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ABSTRACT

The CMG (Cdc45, MCM, GINS) helicase is required for cellular proliferation and
functions to unwind double-stranded DNA to allow the replication machinery to duplicate
the genome. Cancer cells mismanage helicase activation through a variety of
mechanisms, leading to the potential for the development of novel anti-cancer
treatments. Mammalian cells load an excess of MCM complexes that act as reserves for
new replication origins to be created when replication forks stall due to stress
conditions, such as drug treatment. Targeting the helicase through inhibition of the
MCM complex has sensitized cancer cells to drugs that inhibit DNA replication, such as
aphidicolin and hydroxyurea. However, these drugs are not used in the clinical
management of cancer. We hypothesized that the effectiveness of the clinically relevant
drugs gemcitabine and 5-FU against pancreatic cancer cells, and oxaliplatin and
etoposide against colorectal cells, could be increased through co-suppression of the
MCM complex. The oncogene c-Myc also leads to the mismanagement of CMG
helicases in part due to a non-transcriptional role in overactivating replication origins
and causing DNA damage. We sought to elucidate the mechanism by which Myc
causes overactivation of CMG helicases.
Herein we demonstrate that co-suppression of reserve MCM complexes in
pancreatic or colorectal cancer cell lines treated with clinically applicable
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chemotherapeutic compounds causes significant loss of proliferative capacity compared
with cells containing the full complement of reserve MCMs. This is in part due to an
inability to recover DNA replication following drug exposure, leading to an increase in
apoptosis. Targeting of Myc to genomic sites induced large-scale decondensation of
higher order chromatin that was required for CMG helicase assembly and activation at
reserve MCM complexes. The physiological mediators of Myc, GCN5 and Tip60, are
required for the chromatin unfolding and Cdc45 recruitment.
We conclude that depletion of the reserve MCM complexes causes
chemosensitization of multiple human tumor cell types to several chemotherapeutic
drugs used in the clinical management of human cancer. This argues for the
development and use of anti-MCM drugs in combination with chemotherapeutic
compounds, which has the potential to increase the therapeutic index of existing clinical
compounds. We have also identified a previously unknown role for Myc in normal cell
cycle progression whereby DNA replication initiation is regulated through the assembly
and activation of CMG helicases on Myc-mediated open chromatin regions. Our results
also provide new mechanistic insight into Myc oncogenic transformation in which
overstimulation of DNA replication could result in genomic instability and provide an
explanation for Myc driven oncogenic transformation.
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CHAPTER ONE:
INTRODUCTION

Cancer

Cancer is a group of over 100 distinct diseases characterized by uncontrolled
growth and spread of abnormal body cells. Cancer is caused by both external factors,
such as exposure to carcinogens, and internal factors such as inherited genetic
mutations and immune conditions. Cancer is the second most common cause of death
in the US, with a lifetime risk of 1 in 2 for men and 1 in 3 for women, and is strongly
associated with aging, with 78% of all cancers occurring in people aged 55 years or
older [American Cancer Society 2015]. Cancer prevention and early detection become
keys to managing this disease and reducing cancer-related mortality. While the 5-year
survival rate for all cancer has improved from 49% in 1975-1977 to 68% in 2004-2010,
due to both earlier detection and improved treatments, 1 in 4 deaths in 2015 were
attributable to cancer [American Cancer Society 2015], indicating the great need for
more research into novel treatment strategies. The majority of cancer related deaths
occur due to metastasis from the initial tumor site. The extra cellular burden of the tumor
results in less nutrients and oxygen being available for normal tissue and organ
function.

1

Cancer is a genetic disease resulting from the accumulation of mutations within
the DNA of a cell that result in sustained cellular proliferation. For a disease to be
classified as a cancer, it must share characteristics known as the “hallmarks of cancer”
[1]. These hallmarks are acquired during the multistep generation of a tumor, and
include sustained proliferative signaling, evasion of growth suppressive signals,
resistance to cell death, induction of angiogenesis, enabling of replicative immortality,
evasion of immune destruction, reprogramming of cellular metabolism, and activation of
invasion and metastasis. Two other enabling characteristics that facilitate the acquisition
of these hallmarks are genomic instability and tumor-promoting inflammation.

Loss of Proliferative Control
The most defining characteristic of cancer is sustained chronic cellular
proliferation. Growth promoting signals released by normal tissues dictate entry and
progression through the cell cycle and ensure that a balance is maintained between
proliferation and quiescence [1]. Cancer cells lose control over this balance, and
constantly emit growth-promoting signals to enable their own sustained proliferation,
while simultaneously ignoring any growth suppressive signals released by normal cells.
Somatically acquired mutations and gene amplifications in proto-oncogenes, which are
genes involved in normal cell growth and division, lead to this sustained proliferative
signaling. An example of a proto-oncogene is MYC, which can become upregulated
through gene amplification, retroviral insertion or translocation to a constitutively active
promoter. Up to 70% of all cancers have Myc overexpression, an oncoprotein involved
in activating the transcription of genes that promote entry into the cell cycle [2]. But
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other mechanisms of growth promotion by Myc are being discovered. One of the main
focuses of this dissertation is a novel role Myc plays in promoting oncogenesis through
manipulation of DNA replication, a necessary event for tumor cells to maintain their
oncogenicity.

Genomic Instability in Cancer
The maintenance of genomic stability through detection and resolution of
mutations and aberrant DNA structures is key for successful DNA replication and
maintenance of a normal cellular phenotype. Errors in DNA replication or mutations
caused by carcinogens occur in normal cells, and regulatory surveillance systems have
evolved to detect these genetic alterations and halt the cell cycle while the defects are
repaired. If they cannot be repaired, cell death is triggered. The acquisition of tumor
enabling mutations in the lifespan of a cancer cell often leads to increased mutability,
through breakdowns in the genetic surveillance systems or increased sensitivity to
carcinogens [1]. A large number of defects have been identified in genes involved in
genome maintenance and repair in tumors, leading to loss of control of genomic
integrity that favors cancer progression [1]. Genomic instability in cancer cells is visible
through large deletions, amplifications or rearrangements of chromosomal material.

Current Cancer Treatments
The most common current treatment strategies for cancer are surgical removal,
chemotherapy and radiotherapy. Early detection and surgical removal of cancer often
offers the greatest chance of a cure for cancer [American Cancer Society 2015]. Many
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cancers are not eligible for surgical removal, for example blood cancers, or the cancers
are suspected to have spread to distal body regions. Chemotherapy treatment involves
giving medicines or drugs that target the highly proliferative neoplastic cells. However, it
often affects normal highly proliferative body cells as well as cancer cells and gives rise
to side effects such as nausea, hair loss and leukopenia. Radiation therapy uses highenergy particles to destroy cancer cells, and is often given in combination with surgery
or chemotherapy. While radiation therapy is more targeted than chemotherapy, it can
still damage normal surrounding cells and lead to secondary cancer development later
on. In the past few decades, more targeted therapies have emerged due to a detailed
understanding of the underlying biology surrounding each specific cancer disease. One
of the aims of targeted therapies is to minimize the damage to normal cells, while
maintaining maximum anti-neoplastic efficacy. In Chapter 2 we demonstrate the clinical
need for a targeted anti-MCM complex drug, a protein complex necessary for DNA
replication, to increase the efficacy of current chemotherapy treatments.

The Cell Cycle

For both normal cells and cancerous cells to duplicate and create the next
generation, they must undergo a series of coordinated events known as the cell cycle
[3]. The fundamental steps of the cell cycle are the duplication of the parental genome,
and the division of the parental cell into two daughter cells through cytokinesis [4]. The
majority of body cells are terminally differentiated in a quiescent or senescent state
called G0, in which they are no longer actively cycling through the cell cycle. However,
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actively cycling cells such as tumor cells and highly proliferative normal cells, or cells
stimulated by growth factors to re-enter the cell cycle, traverse through a series of highly
regulated cell cycle stages. The order of the stages of the mammalian cell cycle is Gap
Phase 1 (G1), Synthesis-Phase (S), Gap Phase 2 (G2) and Mitosis (M), (Figure 1.1).

Figure 1.1: The Cell Cycle. The stages of the mammalian cell cycle. The key protein
complexes involved in preparation for the initiation of DNA replication are the preReplication Complex and the CMG Helicase, which form during G1-phase.
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During G1 phase, cells increase protein supplies and grow, but importantly they
also prepare for entry into S phase, where the DNA is replicated. In this project we will
look into more detail about the events occurring in G1 phase that prepare a cell to
replicate its 3 billion base pairs of DNA, by examining the formation of the preReplication Complex (pre-RC) and the replicative CMG Helicase. Once cells reach a
point in late-G1 phase, called the Restriction Point (R-point), the cells no longer need to
receive growth factors in order to complete the cell cycle and are committed to enter S
phase, which marks a point of no return for the cell [5]. The G1-S transition is when the
initiation of DNA replication begins, and is a tightly regulated event, deregulation of
which promotes oncogenesis [6]. The genomic DNA is replicated in S phase, which
results in a doubling of the DNA content of the cell. G2 phase allows continued cell
growth and preparation for cellular division. Mitosis then ensues in which the DNA and
cellular content are evenly divided into two daughter cells, thus creating the next
generation.
Regulatory molecules called cyclins and cyclin-dependent kinases (CDKs)
coordinate the cells progress through the cell cycle [7]. Cyclins are the regulatory
molecules and CDKs are the catalytically active molecules, that when activated by a
bound cyclin, perform phosphorylation reactions on other proteins to activate or repress
them to allow the progression through the various stages of the cell cycle [7]. Levels of
the various cyclins increase or decrease throughout the cell cycle, as different cyclinCDK combinations are required during different stages. Cell cycle progression is also
controlled through three main checkpoint controls, which are points at which the
conditions of the cell are assessed, defects are detected, and the cell cycle delayed
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until favorable conditions are met [8]. The R-Point is one such checkpoint, which
operates 2-3 hours before the G1-S transition [5]. There is also a G2-M phase DNA
damage checkpoint, which checks that the DNA has been replicated and the cell is
prepared for entry into mitosis [9]. The final main checkpoint is the metaphase or
spindle checkpoint point, which operates in mitosis and ensures that the chromosomes
have aligned at the mitotic plate prior to anaphase [9]. Checkpoints ensure that any
replication errors are detected and repaired, and prevent any flawed chromosomal
segregations, with the ultimate goal of preserving genomic stability. Cancer cells differ
from normal cells in that they have lost control over some of the regulatory systems that
control cell cycle progression, and accumulate damage and chromosomal segregation
errors that cause genomic instability and promote tumorigenesis [10].

DNA Replication

DNA replication is one of the most important events in the life of a proliferating
cell, whether normal or cancerous. Complete and accurate DNA replication is crucial to
maintain genomic stability in normal cells, and mistakes in this process can significantly
contribute to carcinogenesis.

Replication Origins
Replication origins are sites of initiation of DNA replication. In prokaryotic
bacteria, there is a single, well defined replication origin on a circular chromosome [11].
In contrast, due to the larger size of their genomes, eukaryotes have hundreds to
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thousands of such replication origins on multiple chromosomes and are activated
throughout S phase in a cell-type-specific manner [11]. The sequence specificity of
these sites varies widely between different eukaryotic species. In the unicellular
Saccharomyces cerevisiae, origin sequences are 10-15 base pair (bp) long, and 3-4
such sequences are spread over a 100-150 bp region. These sequences contain the
highly conserved autonomously replicating sequence consensus sequence (ACS) [12].
In Schizosaccharomyces pombe yeast, replication origins contain 20-50 bp AT-rich
sequences spread over 800-1000 bp [12]. Metazoan origins are less well defined, the
replication origins present in the early embryonic stages of Drosophila melanogaster
and Xenopus laevis require little to no sequence specificity [12]. It appears that in
eukaryotic cells, while some sites have been demonstrated to consistently act as
replication origins, the vast majority of replication origins display little to no sequence
specificity and take the form of broad initiation zones, representing an array of potential
replication initiation sites, in which in a typical S phase only one or two will be used [1215]. DNA that is replicated from a single origin is known as a replicon [16]. Mammalian
replicons vary in size from 50-500 kb, which contrasts with Xenopus laevis replicons
that are spaced only 10-15 kb apart, and appear to replicate in staggered clusters [17].
A number of protein complexes are assembled at eukaryotic replication origins, which
lead to the formation of a bi-directional replication fork.

The Pre-Replication Complex
The first such highly evolutionary conserved protein complex is the preReplication Complex, or pre-RC (Figure 1.2), which in cycling cells is assembled in late

8

mitosis and early G1 phase of the cell cycle [18, 19]. However, in this project we are
using mammalian cells that are released from quiescence (therefore not cycling), and
evidence shows that in these cells pre-RC assembly occurs in late-G1 phase [20, 21].

Figure 1.2: The Pre-Replication Complex. This multi-protein complex forms on
chromatin in cells released from quiescence from middle to late G1-phase, and involves
the recruitment and loading of the MCM2-7 complex in a process called licensing,
limiting replication to one round per cell cycle.

First, the hetero-hexameric origin recognition complex (ORC) 1-6 binds to the
future sites of replication origins. ORC acts as the initiator of origins by selecting the
future replication sites [12]. ORC then recruits Cell division cycle 6 (Cdc6) and Cell
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division cycle 10-dependent transcript 1 (Cdt1) proteins, which are required to recruit
and load the hetero-hexameric Mini-Chromosome Maintenance (MCM) 2-7 complex,
the final step in pre-RC assembly. The genes that encode the MCM2-7 subunits were
originally found in genetic screens for proteins involved in plasmid maintenance, cell
cycle progression and chromosomal mis-segregation [12]. The MCM complex is the
catalytic core of the future CMG (Cdc45, MCM, and GINS) helicase, which is the
replicative helicase that provides the mechanical action to unwind the DNA at the
initiation of S phase [22, 23]. Each MCM subunit is an ATPase and member of the
AAA+ family [24]. The MCM complexes are loaded as a double-hexamer onto DNA,
providing a configuration capable of initiating a bi-directional replication fork [22]. MCM
complexes remain stably tethered to DNA for many hours, and this is important as they
remain dormant until selected to become functional CMG helicases at the G1-S
transition [11]. To ensure that no replication origin initiates more than once per cell
cycle, a mechanism has evolved called ‘licensing’, in which MCM complexes can only
be loaded onto DNA in G1 phase. Licensing inhibits MCM loading outside of G1 phase
through the three inhibitors CDKs, a Cdt1 inhibitor called geminin, and the Cul4containing ubiquitin ligase [11]. By preventing MCM loading in S phase, this ensures
that the newly synthesized DNA is not accidentally re-replicated and due to origin firing
[11]. Once the MCM complexes have been loaded onto chromatin, certain MCM
complexes are then chosen to become CMG helicases.
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The CMG Helicase
Replicative helicases are motor proteins that use ATP hydrolysis to unwind
double-stranded DNA into single-stranded DNA to provide access for the replication
machinery to enter and begin DNA synthesis [25]. The MCM complex was implicated as
the putative replicative helicase due to its isolation and demonstration of limited helicase
activity in vitro [26, 27]. All Mcm proteins were determined equally important for entry
into S phase and activation of late-firing origins after the activation of early-firing origins
[28]. MCM complexes were required both for replication initiation and elongation of
nascent DNA molecules [28]. Dormant MCM complexes are displaced from chromatin
as the replication fork progresses, and are prevented from loading onto the newly
synthesized DNA through licensing [28]. As mentioned earlier, each Mcm protein has
ATPase activity, and the ATPase activity of the whole complex depends on the
coordinated interactions between all six subunits [29]. The Mcm4/6/7 subcomplex
comprises the catalytic core, whereas Mcm2/3/5 serve a regulatory function [29]. The
eukaryotic helicase contains both subcomplexes, i.e. Mcm2-7, for full functionality, and
a gate exists between Mcm2/5 for it to load onto chromatin [25]. The first indication that
the MCM complex wasn’t the complete replicative helicase came from a study analyzing
the role of Cdc45 in replication initiation and elongation. Cdc45 was purified and found
to be in a complex with the MCM2-7 hexamer and the GINS (‘Go, Ichi, Nii and San’;
‘five, one, two and three’ in Japanese) tetramer [30]. Cdc45 and GINS were necessary
for the G1-S transition and the whole complex had ATP-dependent helicase activity
[30]. GINS is required for the progression of replication forks by maintaining the
association between MCMs and Cdc45 within replisome progression complexes [31].
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Thus the replicative helicase is now known as the CMG (Cdc45, MCM and GINS)
helicase (Figure 1.3).

Figure 1.3: The CMG Helicase. Cdc45 and GINS join the pre-loaded MCM complexes
to form the CMG Helicase, the multi-protein complex responsible for unwinding DNA at
the G1-S transition. Once the helicase is activated, it creates a bi-directional replication
fork, with RPA protein binding to the single-stranded DNA.

The CMG helicase components are essential for initiation of DNA replication, and
for the elongation phase of replication [23, 31]. The MCM complex is activated upon
addition of Cdc45 and GINS, and enhances the ATP-hydrolysis of the MCM hexamer
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and enhances DNA substrate recognition [23]. At the G1-S transition, Cyclin A-Cdk2
and Dbf4-Cdc7 kinases activate the CMG helicase, which begin to unwind DNA and
form a bidirectional replication fork [32]. DNA polymerase α/primase and ε along with
Mcm10 are recruited and DNA is synthesized in a 5’ to 3’ direction. As the replicative
helicase unwinds DNA, Replication Protein A (RPA) binds to single stranded DNA,
preventing it from winding back onto itself or forming secondary structures and allowing
DNA polymerase to replicate it [33].

The Pre-Replication Complex and CMG Helicase Stoichiometry
A typical replicon in Xenopus laevis embryonic extracts, which is 10-15 kb long,
contains one ORC hexamer, two Cdc6 molecules, 1-2 Cdc45 molecules, and 20-50
MCM hexamers, which equates to one pre-RC to initiate DNA replication from [17]. The
vast excess of MCM complexes likely leads to the efficiency of DNA replication in these
extracts, and results in dormant MCM complexes that are utilized in replicative stress,
as will be discussed later. The typical mammalian replicon is far larger than the
Xenopus laevis embryonic extracts, ranging from 50-500 kb, with an average of 100 kb
[17]. There are a predicted 104 to 106 replicons per mammalian cell [34]. The pre-RC
and CMG helicase stoichiometry is also significantly different, with mammalian ORC
and MCM complexes far less abundant, and Cdc45 extremely low and rate-limiting for
DNA replication. For every 100 kb in the mammalian genome, there is one ORC
hexamer, 2 Cdc6 molecules, 4-5 MCM hexamers, and only 0.35 Cdc45 molecules [17].
The chromatin bound complement of many of these proteins is even lower, with highaffinity (chromatin-bound) Cdc45 present as 2 molecules per 1400 kb [17]. Cdc45 has
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been shown to be a replication-limiting factor in S. pombe yeast, Xenopus extracts, and
in mammalian cells [17, 35, 36]. The Cdc45 protein in mammalian cells is very stable,
the cell enters and exits S phase with the same number of Cdc45 molecules [17]. The
staggering of replication firing in mammalian cells may be due to the availability of
Cdc45 molecules in those regions, and the same Cdc45 molecules must be reutilized
throughout S phase. Cdc45 levels cannot be manipulated in cells through over- or
under-expression, as this renders cells unviable [17]. However, microinjections of
purified Cdc45 protein into S phase nuclei causes a three-fold increase in replication
foci, indicating the induction of dormant MCM complexes into active CMG helicases
[17]. The limiting nature of the Cdc45 protein provides a molecular explanation for the
larger size of the mammalian replicons compared to those of the Xenopus, as a lower
density of MCM hexamers are competing for more limited Cdc45 proteins to become
active origins. Mammalian cells take ~10-fold longer to replicate their DNA compared
with Xenopus extracts, which is explained by the larger replicons and lack of Cdc45
protein [17]. Quantification of the GINS protein complex has yet to be determined, and
so we cannot speculate on whether it too is rate-limiting like Cdc45, or whether there is
an abundant like with the MCM complexes.
There has been some debate in the literature whether tumor cells up-regulate
pre-RC proteins as a consequence of cellular transformation. In a study from our group,
we compared on an equal cell-to-cell basis the pre-RC and Cdc45 protein levels in the
normal highly proliferative Chinese Hamster Ovary (CHO) cell line and mouse 3T3
fibroblast cell line, to the tumor cell lines HeLa and Wilson [17]. We found no difference
in protein levels between these specific cell types, and used multiple antibodies for each
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protein, and compared the total protein levels in the cells to bacterially-purified human
or CHO proteins. This extremely thorough study is not typical in the literature, and
studies which have concluded there is a difference between normal and tumor cells use
less strict testing criteria, such as loading equal protein levels between cell types, and
using slow growing primary cells lines for comparison [37]. The overall up-regulation
seen in studies like this could be due to the overall proliferative nature of the cancer
cells and protein level increases due to this rapid cell growth and division. Cells need to
be analyzed on a cell-to-cell basis, as we did, to determine if pre-RC protein levels are
up-regulated in tumor cells, which we did not see. However, individual Mcm proteins
have been shown to be up-regulated in human tumors. MCM7 is a known oncogene
and is overexpressed in several tumor types [38, 39]. It has been demonstrated that
Mcm7 interacts with the tumor suppressor protein Retinoblastoma (Rb) [40-42], and
overexpressed Mcm7 likely sequesters Rb away from binding with the CMG helicase
and preventing its activation, thus driving cell replication and cellular proliferation.

MCM Complexes as Tumor Suppressors
Eukaryotic cells license more origins than are necessary for a normal S phase by
loading extra MCM complexes [43]. Functional MCM complexes consist of two
heterohexameric MCM2-7 protein complexes. With 4-5 MCM hexamers per average
mammalian replicon size, this results in one complex needed for replication initiation in
that region, and approximately 2 extra complexes with the potential to become
functional (Figure 1.4) [17]. These dormant or back-up MCM complexes are suppressed
by normal S phase checkpoint kinase activity, but become functional when replication
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forks stall due to the action of replication inhibitor drugs such as hydroxyurea (HU), a
ribonucleotide reductase inhibitor, or aphidicolin, a DNA polymerase inhibitor [15]. This
activation of back-up origins during drug treatment allows maintenance of DNA
replication rates, but can be diminished by targeting of MCM subunits with siRNA, which
leads to a reduction in MCM2-7 levels on chromatin and a reduction in the ability to
recover DNA replication during replicative stress [15]. MCM complexes mark DNA that
has not yet been replicated, and due to replication licensing, MCM complexes can only
be loaded onto DNA in G1 phase of the cell cycle and cannot load more MCM
complexes on DNA in S phase if replicative stress causes forks to stall [15]. The need to
be able to recover DNA replication during S phase stresses would explain why cells
license more replication origins than are needed for a normal replication (Figure 1.4).
A four-fold reduction in one MCM subunit reduces the ability of the whole complement
of back-up MCM complexes to activate origins and recover DNA replication following
fork stalling drug treatment, however, in the absence of replicative stress, short-term
replication is unaffected [15, 44, 45]. Activation of back-up origins does not require
checkpoint activation, they become active from the slowing down of replication forks
leading to an increase in the time before the dormant origins are passively replicated, as
seen by an increase in origin density [15]. While reduction of back-up MCM complexes
allowed normal short-term replication rates, long-term viability was affected following
transient HU or camptothecin treatment [15]. The replication stressing drugs used in this
study are not clinically relevant for cancer treatment. We demonstrate in Chapter Two
that reduction of back-up MCM complexes sensitizes tumor cells to chemotherapy
drugs used in the clinical management of these tumors, through inability to recover DNA
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replication and activation of apoptosis. We also show that tumor cells and normal cells
display differential sensitivity to MCM loss in combination with chemotherapy treatment
[44].

Figure 1.4: MCM Complexes act as Tumor Suppressors. Excess MCM complexes
are loaded onto chromatin to be turned into new CMG helicases when replication forks
stall in S phase due to replicative stresses such as DNA topology or drug treatment.
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Shima et al. demonstrated that back-up MCM complexes/dormant origins were
not just required to recover from the replicative stress of fork stalling drug treatment, but
were also crucial to the cells ability to traverse a normal, unperturbed S phase. They
used a Mcm4Chaos3 allele in homozygous mouse fibroblasts, which has a Phe345Ile
amino acid change that compromises the stability of MCM complexes loaded onto
chromatin and leads to a 60% reduction in the total number loaded (hence reducing the
~2/3rds back-up complement) [43]. This reduction in the back-up MCM complement
lead to the accumulation of stalled replication forks in a normal, unperturbed S phase,
despite normal helicase activity of the remaining MCM complexes, and resulted in
incomplete DNA replication. Replication forks encounter stresses in S phase, such as
the topology of DNA, or fluctuations in nucleotide levels, which stall replication forks and
require activation of a dormant replication origin to rescue the replication of that region
(Figure 1.4). Despite a normal ATR-CHK1 checkpoint pathway, the level of stalled
replication forks observed was not enough to trigger a checkpoint response [43].
Multiple DNA repair pathways become activated in the Mcm4Chaos3 cells; however, these
stalled forks persist into M phase and lead to replication intermediates that interfered
with chromosomal segregation [43]. This lead to increased aneuploidy, chromosomal
breaks, translocations and tetraploidy, all of which are characteristics of the genomic
instability seen in cancer cells, and mice with this mutation were prone to develop a
large variety of cancers [43]. This study indicates that back-up MCM complexes function
as tumor suppressors in a normal, unperturbed S phase, and loss of these dormant
origins may occur at an early stage of carcinogenesis and drive genomic instability [43]
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Chromatin

Eukaryotic double-stranded DNA does not exist in a naked state in the cell
nucleus. The DNA is tightly wrapped around proteins called histones, which then
package the DNA into structural units called nucleosomes [46]. DNA wrapped around
histones is referred to as chromatin, and this structural arrangement allows a genome
that would normally stretch to 2 meters (m) long to be tightly packaged into the nucleus
of a cell the size of 6µm. Each histone unit is a positively charged complex of eight
histone core proteins, comprised of two histone H2A-H2B dimers and a histone H3-H4
tetramer [47]. Core histones interact as dimers in a head-to-tail fashion and they all
possess the histone fold domain, which is three alpha helices linked by two loops [48].
The N-terminal histone tails provide sites for multiple types of post-translational
modifications, such as methylation, acetylation, phosphorylation and ubiquitination [49].
The tails constitute 25-30% of the mass of the histone and provide a large exposed
surface for interaction with other proteins, such as those containing bromodomains [49].
A bromodomain is a 110 amino acid protein domain that recognized acetylated
lysine residues, such as those found on histone tails, and transduce this chromatin mark
to elicit a biological effect [50]. Combinations of histone modifications are read by other
proteins and constitute the ‘histone code’, a language read by these other proteins that
leads to downstream functions [49]. In a single nucleosome, 146-bp of DNA is wrapped
around a histone core, with the histone H1 linker binding the entry and exit sites to the
histone core, securing the DNA in place [51]. Nucleosomes are arranged in different
‘beads-on-a-string’ higher-order conformations depending on the variable length of the
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linker DNA in between each unit, the most common higher-order structures being the
30nm fiber and the 100nm fiber [52]. The tight packaging of DNA into chromatin
structures presents physical barriers to accessing DNA for purposes of transcription,
replication and repair [46]. Areas of the genome that are less tightly compacted are
called euchromatin, and these regions are more transcriptionally active and replicate
first in S phase [46]. Areas of the genome that are more condensed are referred to as
heterochromatin, are less transcriptionally active and replicate later in S phase after the
euchromatin [46].
The manipulation of chromatin structure represents an important regulatory event
for transcription and DNA replication to dictate DNA accessibility. Chromatin remodeling
and the role this plays in DNA replication control has been a very understudied topic,
the attention has been focused on the role in transcriptional activation. Modifications
that cause a chromatin decondensation event lead to increased access of the DNA for
the transcriptional machinery, but it can easily be imagined that this accessibility will
also be beneficial for the DNA replication machinery to begin the process of DNA
synthesis. Two key classes of proteins that are studied in this project manipulate
histone tails through the post-translational modification acetylation. Histone
Acetyltransferases (HATs) add an acetyl group (-COCH3) to histone tails. This results in
partial neutralization of the positive histone charge and decreases the association of
histones with the negatively charged DNA substrate [53]. Chromatin regions containing
acetylated histones are generally associated with increased transcriptional activity.
During DNA replication, histones are synthesized and assembled onto the newly
replicated DNA in a pre-acetylated state, which becomes erased as the new chromatin
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matures [49]. Proteins that remove the acetyl group from histone tails are called Histone
Deacetylases (HDACs). These proteins oppose the reaction caused by HATs, and the
interplay between HAT and HDAC activity plays a fundamental role in many biological
processes that involve acetylation.

The Oncogene Myc

One of the first oncogenes discovered was MYC. In the 30 plus years since its
discovery, over 30,000 articles have been published, and even to this day we are
learning new functions this oncogene performs both in normal cells and on the road to
carcinogenesis. Deregulation of Myc expression may be the driving force in up to 70%
of human cancers [2]. The Myc oncoprotein plays critical roles in cellular proliferation,
cell growth, apoptosis, differentiation, metabolism, and stem cell renewal [2]. Myc also
plays key roles in chromatin structure and DNA replication, the main themes of this
research project. We will explore the history, structure, and functions of this enigmatic
protein, and show how our work contributes new knowledge that is highly relevant for
further understanding the biological roles of Myc.

The Discovery of Myc
In 1911 Peyton Rous isolated a retrovirus that could cause cancerous sarcomas
in chickens. This was the first oncogenic retrovirus discovered, and it was discovered
that the gene within the virus responsible for oncogenesis was SRC, a tyrosine kinase
involved in regulating cell growth and differentiation [54]. When non-infected normal
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cells showed they had the same gene sequences as the viral transforming gene, this
lead to the notion that retroviruses could steal oncogenes from other species and use
them to drive cellular growth, and thus viral proliferation. Using information learnt from
the isolation of SRC, the search for other viruses that could cause cancer began, with
the aim of identifying the human homologues of the transforming sequences within the
virus. An avian acute leukemia virus (MC29) caused a spectrum of cancers, including
sarcomas and carcinomas [54, 55]. The transforming sequence in MC29 was isolated in
1979 and called v-MYC, after the myelocytomatosis virus from which it was originally
isolated [56]. The human homologue of MYC was discovered in 1982 [56].

The Myc Oncogene Family
MYC is a member of a family of oncogenes. The majority of studies have been
conducted on the 454 amino acid long oncoprotein c-Myc (herein referred to as Myc),
named after the cellular homologue of the v-MYC gene was found, and coded by the
MYC gene found on human chromosome 8 [55]. The gene has a large noncoding first
exon, and two additional coding exons [55]. Two major Myc isoforms are present in
vertebrate species, Myc-1 and Myc-2 [57]. Myc-1 is translated from a CUG initiation
codon at the end of exon 1, and gives rise to a 67-kDa protein [55]. Myc-2 is translated
from an AUG codon in exon 2 and produces a 64-kDa protein [55]. The majority of
growing cells express the Myc-2 protein [57], but during development of certain tissues
types, or during oncogenesis of those tissues, other Myc family members are
overexpressed. c-Myc is crucial for development and the c-Myc null phenotype is
embryonic lethal [58].
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The N-Myc oncoprotein is 464 amino acids long and is coded by the MYCN
gene, found on human chromosome 2. It is normally only expressed during
development [54]. It was originally discovered in a panel of neuroblastoma cell lines and
tumor samples [54]. N-Myc overexpression is associated with aggressive disease and
poor outcomes [55]. The gene MYCN can replace c-MYC during mouse development
and allow survival into adulthood and reproduction [59]. Also, when placed under the cMYC promoter, MYCN is similarly regulated and is functionally complementary to c-Myc
for the biological processes of cellular growth and differentiation [59].
The L-Myc oncoprotein is 364 amino acids long and is encoded by the MYCL1
gene on human chromosome 1, and is also only normally expressed in development,
but is found amplified in certain small-cell lung cancers and ovarian carcinomas [55]. cMyc, N-Myc and L-Myc interact with Max, a necessary interaction for transcriptional
activation by the Myc proteins [60]. All three also cooperate with mutant the H-RAS
gene to transform rat embryo fibroblasts and to generate cancers in transgenic mice
[58].
Human, mouse and avian cells transiently express a Myc protein called c-Myc S,
which results from translation from a downstream AUG initiation codon [57]. This protein
has a truncated N-terminal transactivation domain lacking the first 100 amino acids, but
an intact C-terminal DNA binding and protein dimerization domain [57]. This protein
would be expected to be a dominant negative inhibitor of c-Myc proteins, through
binding with Myc-binding partners but not eliciting transactivational events [57].
However, c-Myc S high levels in certain tumors and its transient synthesis during rapid
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cell growth suggest that it does not inhibit the cellular proliferation functions of full-length
c-Myc [57]. The function and regulatory role of this Myc protein is still largely unknown.

The Myc Oncoprotein
Serum stimulation of quiescent cells in culture lead to rapid upregulation of Myc
mRNA, establishing Myc as an immediate early gene [55]. Myc mRNA and protein have
an extremely short half-life (15-30 min), and both are expressed at constant levels in
cycling cells [54, 61]. Myc expression is acutely responsible to extracellular signaling
and is one of the most tightly regulated cellular genes [55]. Many of Myc’s regulators are
themselves oncogenes or tumor suppressor genes [55]. The main and most studied
function of Myc is as a transcriptional activator and repressor. Myc is a nuclear protein
that binds to double-stranded DNA through the basic region (BR) in the C-terminus [62].
Also in the C-terminus is the helix-loop-helix-leucine zipper (HLH-LZ) domain, which is
the dimerization domain for Max-Myc interactions, crucial for the ability of Myc to act as
a transcription factor [54]. There are several highly conserved Myc-box (MB) domains
(Figure 1.5) between c-Myc, N-Myc and L-Myc.
The transactivation domain in the N-terminus allows activation of gene
transcription when the C-terminus is bound to DNA, and it contains MBI and MBII [54].
The MBI domain (amino acids 44-63) contains the Ser62 and Thr58 post-translational
modification sites, and is crucial for Myc and Ras cooperated oncogenic transformation
of rat embryonic fibroblasts (REFs) [54]. Deletion of this domain however still allows
transformation of Rat-1A cells [54]. The MBII domain (amino acids 128-143) is essential
for transformation of both REFs and Rat-1A cells, is crucial for transcriptional activation
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and repression [54], activation of DNA replication (discussed later) and is a domain
necessary for interaction with chromatin modifiers (as discussed later).

Figure 1.5: c-Myc Protein Domains. The c-Myc protein contains several conserved
Myc-box (MB) domains, of which MBI and MBII are contained within the transactivation
N-terminal domain, a basic region for binding to DNA, and a helix-loop-helix-leucine
zipper domain for dimerization with Max in the C-terminus.

The MBIIIa domain (amino acids 188-199) is not conserved in L-Myc, and is
essential for Rat-1A transformation but only has intermediate transforming ability
compared with MBII deletion mutants [54]. The MBIIIb domain (amino acids 259-270) is
conserved but has no function currently assigned to it [54]. The MBIV domain (amino
acids 304-324) contains part of the nuclear localization signal (amino acids 320-328)
and is required for Rat-1A and RK3E focus formation, but not REFs, and is dispensable
for Rat-1A soft agar assays [54]. The BR domain (amino acids 355-369) is the site of
Myc binding to E-box and non-E box sites present in DNA and is necessary for
transformation of primary and immortal cells [54]. The HLH-LZ domain (amino acids
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370-439) is the interaction domain for Max, and is essential for transformation of
primary and immortal cells [54].
Specific serine and threonine residues are phosphorylated on the Myc protein to
regulate its stability and activity, the most important being Thr58 and Ser62 [54].
Phosphorylation of Ser62 stabilizes and promotes Myc activation, but this posttranslational modification then allows phosphorylation of Thr58, promoting the binding of
the tumor suppressor FBW7 to recruit the SCF complex, leading to Myc ubiquitination
and proteosomal degradation [55]. Point mutations at and around the Ser62 and Thr58
residues have been found in some Burkitt and AIDS-associated lymphomas, possibly
driving Myc stability and subsequent oncogenesis [55].

Deregulation of Myc in Cancer
Deregulation of Myc transcription can occur by both direct and indirect
mechanism, leading to cellular proliferation and oncogenic transformation [54]. Unlike
some other common oncogenes, the mechanisms of MYC deregulation that promote
oncogenesis are based on overexpression of the Myc protein product, rather than
activating mutations in the MYC gene sequence [54]. The three mechanisms of Myc
deregulation are insertional mutagenesis, chromosomal translocation, and gene
amplification [55]. Retroviral transduction is the result of the v-GAG-MYC gene driving
oncogenesis [54]. Insertional mutagenesis occurs when a retrovirus integrates into the
genome in a promoter or enhancer region of an oncogene and causes the genes
transcriptional activation. Myc was the first cellular oncogene demonstrated to be
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activated by retroviral promoter insertion [54]. Myc deregulation can occur through
activation of MYC by chromosomal translocation, a common event in hematopoietic
malignancies. In Burkitt Lymphoma, which is driven by activated expression of Myc, one
of the chromosomes containing the Ig heavy and light chains (14, 2 or 22), are
translocated with chromosome 8, containing the MYC gene. Due to the genetic
rearrangements of the immunoglobulin genes to provide an enormous variety of antigen
recognition sites, these chromosomal regions are susceptible to translocations, and the
juxtaposition of MYC to the Ig loci drives lymphomagenesis [54]. The first Myc
transgenic mouse, Eµ-Myc, was developed to model Burkitts lymphoma [55]. Through
studying homogeneously staining regions and double-minute chromosomes in cancer
cell lines, it was discovered that these contained multiple copies of the MYC gene, and
lead to the discovery of MYCN in neuroblastoma cell lines and tumors [54]. Gene
amplification of MYC is commonly detected in solid tumors, unlike chromosomal MYC
translocation which are found in hematopoietic cancers [54]. All three of these
mechanisms of MYC deregulation lead to overexpression of the oncoprotein Myc, which
drives cellular proliferation through increased expression of genes that drive cellular
growth and proliferation, and decreased expression of genes involved in cell cycle
arrest. Overactivation of upstream signaling pathways also leads to increased MYC
mRNA production, creating abnormally high Myc protein levels. This could be due to
activation of hormones or growth factors, the receptors they bind to, or activated
secondary intracellular messengers such as Ras, Src, MEK or ERK, that all converge
on and cause Myc expression [54].
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Transcriptional Activation and Repression by Myc
Myc acts downstream of many cellular signaling pathways, interacts with
dozens of cofactors, and controls the expression of hundreds of specific Myc target
genes [2, 63, 64]. The cofactors recruited by Myc modify chromatin to allow access to
the DNA, and engage the transcriptional machinery allowing gene expression [2]. Myc
was found to bind to specific sites in the genome called canonical E-boxes (CACGTG)
through interacting with Max. Max (Myc-associated factor X) is a bHLH-LZ protein that
binds to the Myc bHLH-LZ domain to form heterodimers, and this interaction is critical
for both transcriptional activation of target genes and cellular transformation by Myc
(Figure 1.6) [2, 55, 65]. Max also forms heterodimers with the Mxd (formally Mad) family
members, which compete with Myc binding to repress Myc-Max gene activation and
mediate transcriptional silencing (Figure 1.6) [2]. Myc-Max heterodimers bind to DNA
and activate transcription through the transactivation domain of Myc (amino acids 1143), by associating with a variety of cofactors, such as TRRAP [2]. Up to 15% of all
genes are predicted to be in the Myc target gene network [66]. Target genes
transcriptionally activated by Myc are typically involved in cell growth, protein synthesis,
ribosomal biogenesis, metabolism, glycolysis, mitochondrial function and cell cycle
progression [67]. Targets genes that are transcriptionally repressed by Myc are involved
in cell cycle arrest, communication between cells, cell adhesion or inhibitors of Mycinduced cellular transformation [67]. It became clear that Myc does not act as a classical
transcription factor. The maximal gene induction is only two-fold, which is considerably
lower than other classical transcription factors [66, 68, 69]. Myc has important biological

28

roles that extend beyond transactivation, including global influences on chromatin
structure and non-transcriptional roles in DNA replication initiation.

Figure 1.6: Myc, Max and Mxd Transcriptional Functions. Myc heterodimerizes with
Max to promote proliferation, whereas Max can also heterodimerize with Mxd to inhibit
growth.

The Role of Myc in DNA Replication
In the early days of Myc research, it was speculated that Myc was directly
regulating DNA replication. Several studies in the late 1980’s indicated that Myc had an
important role in replication, however, the model of Myc being a regulator of gene
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transcription yielded more consistent and comprehensive results and the majority of
effort was placed in this field [54]. More recently, the interest of understanding the direct
role of Myc in DNA replication has been reawakened, largely due to the efforts of the
Gautier Laboratory who conduct many of their experiments in a transcriptionally inert
system. In Chapter 3, we will demonstrate a novel mechanism for Myc-mediated control
over DNA replication.
Two reports from Ariga and Ariga, published in 1987, were the first to suggest a
direct role for Myc in DNA replication. They showed that a plasmid containing mouse
liver DNA could replicate in vivo and in vitro only if c-Myc was present, and that by
transfecting an anti-c-Myc antibody, this replication could be inhibited [70]. They also
detected c-Myc binding activity at the replication initiation site in the plasmid, and
suggested that c-Myc promotes DNA replication through binding to origin sequences
[70]. In a separate study this group then looked at whether the DNA replication function
of c-Myc was similar to that of SV40 T antigen, and showed that c-Myc could be
substituted for the T antigen for SV40 DNA replication [71]. SV40 Large T antigen acts
as a helicase to unwind DNA containing the SV40 replication origin [72]. This could
suggest that c-Myc is present at replication origins due to it being in a helicase complex.
In 1989 there was a report of an intriguing correlative observation in early
embryonic Xenopus laevis relating to c-Myc. Vast quantities of unusually stable
maternal c-Myc protein were found in Xenopus laevis oocytes, and located in the
cytoplasm, in contrast with somatic cells in which it is located in the nucleus [73]. Upon
fertilization, the c-Myc protein is rapidly translocated to the nucleus as it prepares to
initiate DNA replication, and the level on a per cell basis decreases exponentially as
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rapid cell division occurs exponentially [73]. Cell cycle progression and DNA replication
in the early Xenopus embryos do not rely upon transcription, indicating that Myc is
providing an unknown non-transcriptional function during the replicative period. Once
the maternal c-Myc supplies are depleted, the embryos are capable of transcription and
translation of its own Myc mRNA.
To facilitate the study of the functions of the Myc oncoprotein, a hormoneactivated Myc fusion protein was created by M. Eilers in 1989 [74]. The hormone
binding domain of the estrogen receptor gene was fused to the 3’ end of MYC, creating
a MYCER gene that produced a 100kDa MycER protein. This protein was demonstrated
to be activated by estrogen or hydroxytamoxifen (4-OHT) addition, to migrate to the
nucleus, and caused soft agar colony growth, an indication of transformation [74]. The
mutant ΔMycER protein missing MBII did not cause soft agar colony growth.
Transformation by MycER was reversible through removal of hormone activation [74].
Cells infected with retroviruses containing MycER plasmids are grown in media lacking
phenol red and containing charcoal-stripped serum, in an attempt to remove any
estrogen hormone or hormone-like chemicals that could inadvertently activate the fusion
protein during normal cell culture. The ER domain was shown to not contribute to
transcriptional activation on its own, so this was not contributing to the observed
transformation phenotype elicited solely by Myc [74]. In chapter 3 we utilize the MycER
and ΔMycER system as described here. A report using the chimeric MycER and
ΔMycER proteins in non-transformed, EGF-dependent, immortalized BALB mouse
keratinocyte (MK) cells, demonstrated super-incorporation of radioactively labeled
thymidine during S phase upon MycER induction in early G1 phase, but not upon
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ΔMycER induction [75]. Expression of several Myc sensitive genes involved in cell cycle
progression, cyclins A, E and D1, were unaffected by Myc induction [75]. Histone H1
kinase activity associated with an E2F-1 complex containing cyclin A and Cdk-2 is
increased in late-G1 and early-S phase [75]. The MBII domain has now been shown to
be crucial for transformation, transactivation and DNA replication initiation.
Gautier et al. published a Nature paper in 2007 conclusively demonstrating a
non-transcriptional role for c-Myc in control of DNA replication [14]. Both c-Myc and NMyc were shown to be in complexes with many pre-RC proteins, which were the MCM27, Orc2, Cdc6, Cdt1, and Myc’s binding partner Max was also present in these
complexes [14]. At the time of this study, the full complement of the replicative helicase
was unknown, so Cdc45 and GINS were not examined. Proteins involved in DNA
elongation, Mcm10, PCNA and RPA32, were absent from these complexes [14]. Myc
was found co-localized with BrdU foci in early-S phase only, an indication that Myc is at
sites of DNA synthesis. Myc was found at two replication origins, lamin B2 and c-Myc,
for which it is known that Myc does not cause transcriptional activation of these genes
[14]. It was known that Myc was necessary for the G1-S transition to occur, but whether
this was because Myc was needed to transcriptionally induce S phase promoting factors
or because Myc was needed to associate with the replication apparatus was not known
[14]. By fusing G1 cells to S phase cells, which could provide the necessary cyclin-cdk
complexes, and using cyclohexamide to inhibit further protein synthesis, it was shown
that c-MYC-/- cells could not progress into S phase, but c-MYC+/- cells could [14]. This
finding suggests Myc controls mammalian DNA replication initiation in part due to a nontranscriptional role. In Xenopus cell-free extracts, which are transcriptionally inert, full-
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length Myc was also necessary for DNA replication to occur, and depletion of Myc
caused a decrease in the overall number of active replication origins but not a decrease
in the replication fork progression rate [14]. In both mammalian cells and Xenopus
extracts, the pre-RC complex loaded onto chromatin, suggesting Myc is having an effect
after pre-RC assembly but before helicase activation [14]. Expression of MycER caused
an increase in the number of DNA replication foci in early-S phase, which was not
affected by α-amanitin, a transcriptional inhibitor [14]. Myc overexpression in Xenopus
extracts caused an increase in the amount of endogenous Cdc45 localized on
chromatin, and in mammalian cells caused an increase in the amount of HA-tagged
exogenous Cdc45 on chromatin, partially indicating there could be more CMG helicases
assembled [14]. While this study clearly demonstrates overexpressed Myc causes an
increase in DNA replication in S-phase, the mechanism behind how this occurs is not
known.
This study also looked at the effect overexpressed Myc has on DNA damage.
Increased origin firing is a source of replicative stress, and Gautier et al showed that
exogenous Myc caused an increase in histone H2A.X Ser 139 phosphorylation, an
indicator of DNA damage in mammalian cells and Xenopus extracts [14]. This effect
was inhibited by Geminin, which blocks MCM loading of the pre-RC. Overexpressed
Myc activated the ATM/ATR-Chk1-dependent checkpoint in Xenopus extracts as DNA
damage appeared [14]. Myc induced DNA damage could be a contributing factor to the
genomic instability of Myc amplified tumors, another study showed that in as few as 2
cell cycles, Myc can induce genomic instability [76]. Myc overexpression may be an
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early step in oncogenesis that allows further mutations to accumulate through the
induction of genomic instability [77].
Gautier’s group published another report in 2013 in which they used DNA strand
stretching to visualize replication initiation sites and the effect Myc overexpression had
on them. Myc overexpression caused earlier firing of origins, a reduction in the
interorigin distance and an increase in the number of origins firing, indicating overusage of origins (presumably by using the back-up MCM complexes discussed earlier)
[78]. This result matches the previous results in the literature showing that
overexpressed Myc caused an increase in the number of BrdU foci and increased
thymidine incorporation [14, 75]. Replication elongation following origin firing is normally
symmetrical, however, with Myc overexpression, the number of asymmetrical origins
increased, suggesting Myc is triggering replication fork stalling events [78]. Based on
their previous finding that Myc overexpression caused an increase in chromatin-bound
Cdc45, they overexpressed Cdc45 and saw that it recapitulated the Myc phenotype of
increased origin usage and asymmetrical forks [78]. Co-overexpression of both Myc and
Cdc45 did not have an additive effect, suggesting they function on the same pathway.
Similar effects were seen with GINS overexpression. Myc induced replicative stress and
DNA damage was dependent on Cdc45 presence, suggesting Myc is acting upstream
of CMG helicase functionality [78]. Origin activation requires the activity of cyclin E/Cdk2
complexes, and Myc is known to antagonize p27, an inhibitor of cyclin E/Cdk2
complexes [78]. They found that Myc lowers the threshold of CDK activity required for
Cdc45 recruitment and origin activation [78]. Whether this is the sole mechanism for
how Myc promotes CMG helicase assembly or activation was not known at this point,
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and in Chapter 3 we act a new mechanism that could also be involved in origin
activation.
Myc has been shown to directly interact with Mcm7, presumably through the Cterminus since N-terminal deletion did not affect the interaction, which required the
presence of the MBII domain [79]. Myc may be directly interacting with the pre-RC and
CMG helicase through Mcm7 binding, but the biological effect this interaction would
have is unknown. The tumor suppressor protein Retinoblastoma (Rb) is known to
interact with and inhibit the CMG helicase through binding to the C-terminal of Mcm7
[42]. It could be possible that Myc and Rb are competing with each other for the same
binding location on the CMG helicase, and whereas Rb binds to inhibit its function, Myc
could be binding to promote helicase activity and thus DNA replication. The Mcm7 gene
is also a transcriptional target of N-Myc, and neuroblastoma tumors with N-Myc
amplification have a 10-fold higher Mcm7 protein level [80]. Overexpression of Mcm7
may sequester Rb and prevent its inhibitory binding to the CMG helicase, while
concurrent N-Myc amplification allows Myc to bind to and activate the helicase instead.

The Role of Myc in Chromatin Modifications
For transcription factors to facilitate the binding of RNA polymerase to
transcription initiation sites, the condensed chromatin must be remodeled via ATPdependent restructuring of nucleosomes to provide access to the DNA, and histone
modifications for other proteins to read to recruit transcriptional activators or repressors
[2]. Myc had long been thought to act solely as a classic transcription factor, regulating
a small set of target genes through discrete chromatin modifications at their promoters
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[81]. A large number of genomic studies have now demonstrated that Myc binds to tens
of thousand of sites throughout the genome, as many as half these sites are significant
distances from promoters, and Myc regulates global chromatin modifications, far more
than a classic transcription factor [81]. More than a thousand putative target genes have
been identified for Myc, and Myc is though to regulate the gene expression of up to 15%
of all genes [81].
Myc binds to genomic sites that already contain certain histone acetylation and
methylation marks, namely, H3K4me2, H3K4me3, H3K79me2, H3K9ac and H3K18ac
[82]. Once bound to chromatin, through interactions with chromatin modifiers Myc
induces further acetylation of histones H3 and H4, specifically H3K9, H3K14, H3K18,
H4K5, H4K12, H4K8, H4K91 and H2AK5 [82]. Most Myc targets display multiple histone
marks. Ablation of N-Myc in neuronal progenitor cells results in histone hypoacetylation
of H3 and H4 and loss of methylation marks such as H3-triMeK4, a sign of chromatin
inactivation, and condensed nuclei [83]. This was rescued by expression of exogenous
N-Myc, but depended on the presence of the MBII domain [83]. Loss of Myc also
negatively affects DNA accessibility, as measured by MNase accessibility assays,
leading to loss of euchromatin [83]. Myc was found present at the lamin B2 replication
origin in early G1-phase and this was associated with nucleosome remodeling,
indicating that Myc affects chromatin to allow greater accessibility to cellular machinery,
potentially involved in processes such as DNA replication [84]
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Myc Associated Histone Acetyltransferases
Histone acetylation is catalyzed by a variety of histone acetyltransferases
(HATs). HATs enzymatically transfer an acetyl group from acetyl-coenzyme A to
specific lysine residues found on histones [82]. Myc interacts with a number of different
chromatin modifying enzymes, but the majority of studies have focused on the
interaction with the HATs GCN5 and Tip60 [2]. Myc interacts with a nuclear cofactor
called TRRAP (transformation-transactivation domain associated protein) through the
MBII domain, and TRRAP is essential for oncogenic transformation by Myc [85, 86].
TRRAP is a large protein that lacks a kinase domain, but serves as a scaffold for
assembling multiprotein complexes including HATs [2]. GCN5 is a direct Myc target
gene, and also recruited to promoter regions by Myc [2, 83]. GCN5 preferentially
acetylates H3 (K9/14/18) [2]. Myc recruits both TRRAP and GCN5 through direct
physical interaction of the MBII domain with the human STAGA (SPT3-TAF-GCN5)
coactivator complex [87]. GCN5 protein expression is required for Myc to acetylate
histones, suggesting one of the main ways Myc modifies chromatin is through
recruitment of GCN5 to acetylate histone tails [83]. TRRAP can also contain the HAT
Tip60 instead of GCN5, and Tip60 is recruited to chromatin by Myc [2, 88]. Tip60
preferentially acetylates H4 (K5/8/12) and H2AK5 [2]. Overexpression of an
enzymatically mutant Tip60 delays Myc induced acetylation of histone H4 and reduces
the amount of Myc binding to chromatin [88]. Both GCN5 and Tip60 are Myc cofactors
that are recruited to chromatin by Myc, and cause acetylation of histones that are
associated with open, accessible chromatin, which would benefit both transcriptional
activation, and potentially DNA replication initiation, as discussed in Chapter 3.
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Myc Associated Histone Deacetylases
Histone deacetylases (HDACs) remove acetyl groups from histones. Myc-Max
function is antagonized by another transcription factor complex containing Mxd-Max,
which block Myc-Max function by recruitment of either mSin3A or mSin3B, which in turn
recruit either HDAC1 or 2 [86]. Overexpression of Mxd results in a reduction in global
acetylated H3 and H4, which depends on the presence of the mSin3-HDAC binding
domain [83]. The global deacetylation of nucleosomal histones results in a closed,
transcriptionally inert chromatin state. Overexpression of Max does not affect global
chromatin structure, as expected since Max is required for the opposing functions of
both Myc and Mxd [83]. By using a HDAC inhibitor, the histone hypoacetylation in NMyc null cells was reversed; suggesting the role of Myc in chromatin modifications is to
shift the balance towards HATs and away from HDACs [83].

Targeting Myc for Cancer Therapeutics
With up to 70% of cancers displaying deregulation of Myc expression, strategies
are being explored to target Myc therapeutically. Oncogene addiction is the
phenomenon displayed by some cancers that depend on a single oncogene for
sustained proliferative growth. Experimental models of cancers driven by Myc have
suggested that some tumors are addicted to Myc, as activation of Myc elicits genomic
instability or tumor formation, but subsequent inactivation of Myc causes regression of
established tumors and a loss of the transformative phenotype [74, 76, 89]. Targeting
Myc therapeutically has been challenging due to its necessary role in normal cells, the
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diverse mechanisms driving its overexpression, and the challenge of disrupting proteinDNA interactions [90]. Pharmaceutical strategies so far have attempted to inhibit Myc
expression, interrupt Myc-Max binding to each other and to DNA, and interfere with Myc
target genes [91].
BET (bromodomain and extra-terminal) bromodomain family members, such as
BRD2, BRD3 and BRD4, recognize and associate with acetylated chromatin and
modulate transcriptional activation through recruitment of transcriptional regulators [90,
92]. Myc recognizes pre-acetylated histones and binds to such regions and increases
the histone lysine acetylation. A selective small molecule inhibitor of BET
bromodomains, JQ1, displaces BET bromodomains from chromatin by competitively
binding to the acetyl-lysine recognition pocket [92]. JQ1 was used in multiple myeloma,
leukemia and lymphoma cell lines, which often has a translocation of Myc, and it
inhibited Myc transcription and Myc protein levels and lead to downregulation of the Myc
transcriptional program, causing cell cycle arrest and senescence [90, 92]. These
studies demonstrate that inhibition of Myc through targeting BET bromodomains might
be of therapeutic value for the treatment of cancer patients. A small molecule inhibitor of
Myc-Max dimerization called Mycro3 was found shrink pancreatic tumors in mice with
KRAS* mutations dependent on Myc activity, and also saw increases in apoptosis and a
reduction in proliferation [93]. Other therapeutic strategies have focused on targeting
Myc target genes, such as viral expression of a Myc-repressed microRNA called miR26a which yielded remarkable responses in a liver cancer model [91]. Sumoylation of
Myc is essential for tumor growth, so perhaps this can be exploited therapeutically [91].
Myc induces replicative stress, which can make cells more sensitive to a variety of
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drugs such as chemotherapeutic agents, replication inhibitors and checkpoint inhibitors,
as discussed in Chapter 3. There is a drug in phase 1 of clinical trials in patients with
solid tumors called DCR-MYC is a synthetic double-stranded RNA that targets Myc, but
whether this proves to be beneficial to patients in currently unknown (Clinicaltrials.gov).
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CHAPTER TWO:
SUPPRESSION OF RESERVE MCM COMPLEXES CHEMOSENSITIZES TO
GEMCITABINE AND 5-FLUOROURACIL

Note to Reader

Portions of this chapter have been previously published in Molecular Cancer
Research, 2015, Sep;13(9):1296-305, and have been reproduced with permission from
AACR publishing (see Appendix).

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest cancer
survival rates due to its late diagnosis and lack of effective treatment regimens.
Chemotherapeutic drugs such as gemcitabine and 5-fluorouracil (5-FU) are used to
treat PDAC patients. These drugs act as indirect blockers of DNA replication through
causing the stalling of replication forks and thus inability to successfully complete S
phase. However, these drugs display only modest efficacy and do not stop the
progression of this deadly disease. There is a strong need to develop novel and
innovative therapeutic approaches to improve PDAC patient survival. Recent studies
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have indicated that suppression of the MCM helicase may provide a novel means to
sensitize cancer cells to chemotherapeutic drugs that inhibit replicative fork progression.
Mammalian cells assemble an excess of MCM complexes onto DNA, greater than the
amount needed to initiate and complete S phase. The reserve MCM complexes are
utilized in conditions of replicative stress, in which they are converted into active
replication origins to recover from stalled replication forks. Herein we provide definitive
evidence that co-suppression of the reserve MCM complexes sensitizes PDAC tumor
cell lines to both gemcitabine and 5-FU, leading to increased loss of proliferative
capacity compared to drugs alone. This is due to an inability to recover replication
following chemotherapy drug exposure due to reduced levels of reserve MCM
complexes, leading to an increase in apoptosis. PDAC tumor cells are more sensitive to
MCM loss in the presence of gemcitabine than are non-tumor, immortalized epithelial
cells. Our results apply to other cancer types, as colon tumor cells experienced loss of
proliferative capacity when exposed to the crosslinking agent oxaliplatin or
topoisomerase inhibitor etoposide when the reserve MCM complexes were depleted.
Neither of these chemotherapy drugs alone is effective at treating colorectal cancer, but
our strategy has increased their efficacy. These studies demonstrate that suppressing
the reserve complement of MCM complexes provides an effective sensitizing approach
with the potential to increase the therapeutic index of drugs used in the clinical
management of PDAC and other cancers.
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Introduction

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. The
5-year survival rate is only 7% due to its symptomless early stages, and thus late
diagnosis. In the US in 2015 an estimated 48,960 new cases were diagnosed, and
40,560 deaths were expected [American Cancer Society 2015]. It affects men and
women equally, is the eighth most common cancer but the fourth most common cause
of cancer-related death [American Cancer Society 2015]. There are no reliable early
detection screening programs, and less than 20% of patients at diagnosis are surgical
candidates due to the fact that it has already spread [American Cancer Society 2015].
Such patients are usually treated with chemotherapeutic agents to extend their lives.
Chemotherapeutic interventions for advanced pancreatic cancer often include
gemcitabine, or a combination chemotherapy regimen including 5-fluorouracil (5-FU)
[94, 95]. The mechanism of action of many currently used chemotherapeutic agents
targets DNA replication, leading to cellular death. 5-Flurorouracil is an inhibitor of
nucleotide synthesis. The nucleoside analog Gemcitabine indirectly inhibits DNA
polymerase through incorporation into replicating DNA, resulting in partial chain
termination and stalling of replication forks [96]. These drugs cause replication forks to
stall and thus indirectly suppress DNA replication and S phase. However, these drugs
only demonstrate modest efficacy against PDAC disease progression and are
associated with toxic side effects, which make them unsuitable for certain patients [95].
Colorectal cancer is the third most common cancer in men and women,
accounting for 8% of the total new cancer cases in the US in 2015 [American Cancer
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Society 2015]. It is also the third most common cause of cancer related death, due to
slow uptake on the colorectal screening programs and relatively symptomless early
stages of the disease [American Cancer Society 2015]. Etoposide is an anthracycline
that intercalates into the DNA and inhibits topoisomerase II-DNA complexes, causing
double-stranded DNA breaks [96]. Thus the development of novel innovative strategies
to increase the efficacy of the existing chemotherapeutic compounds used to treat
PDAC and colorectal cancer, and at lowered doses to reduce their toxicity, would be
beneficial to cancer patients due to increased therapeutic index of current drugs in
clinical practice.
Suppression of the MCM complex has been demonstrated to increase the
efficacy of drugs that slow or inhibit DNA replication through stalling of replication forks
[15, 45, 97]. The MCM complex is a heterohexameric ATPase complex comprised of
Mcm2-7 subunits. The MCM complex forms the core of the replicative helicase and it is
loaded onto DNA in excess during G1 phase of the cell cycle in a process called
licensing, which limits DNA replication to a single round per cell cycle [98-100]. In lateG1 phase, certain MCM complexes are chosen to become active replicative helicases
when Cdc45 and the GINS protein complex are recruited to the core MCM complexes,
forming the CMG helicase (Cdc45, MCMs, GINS) [23, 101, 102]. The active CMG
helicases represent the functional origins of DNA replication and proceed with the
replication forks during elongation [23, 102-104]. In mammalian cells an excess of MCM
complexes is loaded onto DNA during G1 phase than are necessary to initiate and
complete S phase. This is because MCM complexes can only load in G1 phase and
cannot be loaded in S phase if replicative stresses occur [15, 45, 97-99, 105, 106].
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These are called dormant or reserve MCM complexes, and several studies have
estimated that this excess is 3-10 times the number needed for a successful replication
[15, 17, 45]. The excess of MCM complexes serves as back-ups for cells when they are
subjected to replication stresses during S phase, such as topological issues, nucleotide
fluctuations, or after exposure to replication-fork slowing drugs including
chemotherapeutic agents [15, 45].
Several studies have shown that loss of reserve MCM complexes causes tumor
cells to become chemosensitized to replication fork stalling drugs. The MCM complex
works as a hexamer, reduction of one subunit reduces the ability of the whole complex
to load and function on chromatin [43]. The depletion of Mcm5 in U2OS osteosarcoma
tumor cells by two-thirds of its normal level reduces the reserve complexes of normal
levels, and while this does not effect proliferative capacity alone, it causes sensitivity to
aphidicolin (a DNA polymerase inhibitor) and hydroxyurea (HU; a ribonucleotide
reductase inhibitor) [15]. However neither of these drugs is used clinically in the clinical
management of cancer. A similar anti-proliferative sensitizing effect was observed when
Mcm5 suppression occurred in combination with exposure to the chemotherapy drug
camptothecin (a topoisomerase inhibitor) [15]. Hypersensitivity to Aphidicolin and HU is
observed in HeLa cells with severely reduced (5-10% of normal levels) Mcm2 or Mcm3
to ~5-10% of normal levels [45]. Drug sensitization in U2OS, HeLa, and MDA-MB-231
tumor cells to HU and hydrogen peroxide is also seen by reducing proteins involved in
the assembly and loading of the MCM complex, ORC (origin recognition complex) or
Cdc6 proteins, via loss of viability and proliferative capacity [107].
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The studies described above indicate that a full complement of MCM complexes
are required for cells to remain viable after exposure to certain drugs that slow or block
replication fork progression and thereby cause S phase stress. Reduction of the reserve
MCM levels produces hypersensitivity to replication inhibiting drugs through a decrease
in the proliferative capacity of the cellular population. These findings could have
applications to the study of anti-tumorigenic therapies. As a hypothesis, co-suppression
of the MCM complex offers the opportunity to augment the efficacy and anti-tumor
activity of existing chemotherapeutic agents that negatively affect replication fork
activity. However, with the exception of camptothecin, the drugs used so far to
investigate this chemosensitization concept are aphidicolin and HU, which are not
suitable for use in the clinical management of human cancer [15, 45]. The
chemotherapeutic agents gemcitabine and 5-FU are used in clinical management of
PDAC, oxaliplatin and etoposide are used to treat colorectal cancer, and these drugs
function by indirectly blocking replication fork activity [95]. From the previously
mentioned studies, it can be inferred that the efficacy of gemcitabine and 5-FU against
PDAC cells, and oxaliplatin and etoposide against colorectal cells, could be increased
through co-suppression of the MCM complex. However, this concept has yet to be
conclusively demonstrated.
In this study we utilized PDAC and colorectal tumor lines as a model system to
explore a method for increasing the therapeutic index of clinical drugs. Herein we
present definitive evidence that co-suppression of the reserve MCM complexes
chemosensitizes PDAC cell lines to gemcitabine and 5-FU, and colorectal cells to
oxaliplatin and etoposide, all of which are indirect inhibitors of DNA replication. Partial
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loss of MCMs through siRNA treatment reduces the reserve complement of MCMs
significantly reduces the proliferative capacity of PDAC cells beyond that achieved
through the drug treatment of gemcitabine or 5-FU alone. The mechanism behind this
chemosensitivity is the inability of the tumor cells with reduced MCM levels to recover
DNA replication following exposures to gemcitabine. We compared the chemosensitivity
to gemcitabine of non-transformed epithelial cell line to PDAC cells in the context of
depleted reserve MCM complexes and found that the normal cells were not sensitized
to the same drug dose as the tumor cells were. We also show that MCM co-suppression
causes an increase in the apoptotic index of colorectal cancer cells exposed to
oxaliplatin or etoposide, two chemotherapeutic agents that act indirectly on DNA
replication and are used in the clinical management of colorectal cancer and other
tumor types, but with toxic side effects [108]. The chemotherapeutic compounds we
tested only have modest anti-tumor activity and can cause toxic side effects that limit
patient tolerance [94, 95, 108-111]. This study provides a proof-of-principle that the
development of anti-MCM drugs in the future has the potential to increase the
therapeutic index of existing anti-neoplastic drugs and may apply to many tumor types
other than those tested.
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Materials and Methods

Cell Culture, Transfections and Drugs
Panc1, Colo357, and HaCaT [112] cells were cultured in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum (Hyclone), and SW480 cells
were cultured in RPMI medium containing 10% fetal bovine serum. Transfections
utilized Dharmafect reagent according to manufacturer methods (Thermo Scientific). For
clonogenic and apoptosis assays, cells were seeded at 50% density and transfected the
next day (time 0-hr) with 1-3nM of siRNA targeting HsMcm7 or HsMcm4 (siGenome
Smartpools, Thermo Scientific), or with non-specific control siRNA (siGenome control,
Thermo Scientific). Exposure to siRNA pools occurred for 120 hrs (for clonogenic
assays), or for 72 hrs (for SW480 apoptosis assays and Panc1 DNA replication
recovery assays). Exposure to drugs occurred concurrent with siRNA treatment from
72-120 hrs (for clonogenic assays), 24-72 hrs (for SW480 apoptosis assays), or 72-78
hrs (for DNA replication recovery assays). Aphidicolin, gemcitabine, 5-fluorouracil,
oxaliplatin, and etoposide were purchased from Sigma-Aldrich and used at
concentrations indicated.

Immunoblotting and Antibodies
For verifying successful siRNA knockdowns of MCM proteins by immunoblotting,
equal numbers of cells were scraped off plates into cold PBS, lysed and boiled in 1X
Laemmli loading dye (for total lysates) and analyzed by standard immunoblotting
techniques [17]. An aliquot of scraped cells were removed and resuspended in a
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HEPES-buffered pH 7.5 solution containing 10mM EDTA to perform cell counts on a
hemocytometer without using trypsin. Chromatin enrichment of samples was conducted
as follows. Cells were resuspended in buffer A (10mM HEPES pH 7.9, 10mM KCl,
1.5mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 5 µg of aprotinin per ml, 5 µg
of leupeptin per ml, 0.5 µg of pepstatin A per ml, 0.1 mM phenylmethylsulfonyl fluoride)
containing 0.1% Triton X-100 for 5 mins on ice. Nuclei were isolated by low-speed
centrifugation (5 min, 1,300 x g 4°C), washed in buffer A without TX-100, and then lysed
in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, and previously described protease
inhibitors) for 30 mins on ice. Insoluble chromatin was collected by low-speed
centrifugation (5 min, 1,700 x g 4°C) and resuspended in an equal volume of buffer B
and 2X Laemmli loading dye.
To determine the degree of partiality of siRNA knockdown for Mcm7 and Mcm4,
samples from 72 hrs of knockdown were compared to serially titrated samples from
non-transfected control cells. Percentages of the control lysates loaded are indicated in
the figures, with 100% control lysate representing an equal amount of cell-number
lysate relative to the si-Mcm7 or si-Mcm4 knockdown samples. Antibodies and
concentrations used for immunoblots were mouse monoclonal anti-Actin (1:10,000;
Sigma), mouse monoclonal anti-Mcm7 (1:1,000; Santa Cruz), and chicken polyclonal
anti-Mcm4 (1:1,000) generated by Aves Labs [17]. Mouse monoclonal anti-Orc4 (1:500)
was from BD Transduction Laboratories.
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Cell Proliferation and Apoptosis Assays
For clonogenic assays, cells were seeded at 50% density and transfected the
next day (time 0-hr) with 1-3nM of siRNA targeting HsMcm7 or HsMcm4 (siGenome
Smartpools, Thermo Scientific), or with non-specific control siRNA (siGenome control,
Thermo Scientific). Prior to drug exposures, cells were reduced in density 48 hrs after
siRNA transfections by splitting 1:1000 into new duplicate 35mm plates (to allow better
colony visualization). Transfected and non-transfected cells were exposed to drugs
concurrently with siRNA treatment from 72-120 hrs, and allowed to culture for the
remainder of two weeks. Cells were then fixed and stained with Giemsa to quantify
surviving colony numbers.
For apoptosis assays, SW480 cells were not split after siRNA transfections.
Transfected and non-transfected cells were exposed to drugs concurrently with siRNA
treatment from 24-72 hrs. Apoptosis assays were then conducted using an Annexin-V
staining kit (BD Biosciences) and flow cytometric analyses according to manufacturer
methods.

DNA Replication Recovery Assays
Equal cell numbers of asynchronous Panc1 cells plated in 24-well dishes were
transfected with 100nM siRNA against Mcm7, Mcm4, or si-control for 72 hrs. This
achieved an ~ 90-95% partial reduction of Mcm7 protein for acute testing of DNA
replication recovery. Parallel plates were not transfected as comparisons. Cells were
exposed to 100nM gemcitabine for 6 hrs, and medium was changed (at time 0) to
remove drug and siRNAs. Cultures were pulsed for 30 minutes in duplicate or triplicate
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with 3µCi/mL tritiated-thymidine at the times indicated, and subsequently fixed with 1 M
ascorbic acid. Trichloroacetic acid (TCA) precipitable material was processed for
scintillation counting as described [113]. The average counts per minute (cpm) were
determined from one-third of each sample, and plotted to measure DNA replication
rates for each condition and time after drug removal.

Results

Depletion of Reserve MCM Complexes Sensitizes Panc1 PDAC Cells to
Gemcitabine and 5-Fluorouracil
Suppression of the reserve MCM complexes in osteosarcoma and HeLa tumor
cell lines causes chemosensitization to the anti-proliferative effects of aphidicolin and
hydroxyurea [15, 45]. These drugs act by directly or indirectly blocking DNA replication
through inhibiting the progress of the replicative forks during S phase. A hypothesis
from these studies is that chemotherapeutic drugs that also indirectly inhibit replication
forks and are used in the clinical management of cancer could be made more effective
in their anti-proliferative effects when used in combination with a reduction of reserve
MCM complexes. To test this idea we used pancreatic ductal adenocarcinoma (PDAC)
tumor cell lines as a model system, due to the need for novel experimental strategies to
treat this deadly disease. The chemotherapeutic drugs gemcitabine and 5-fluorouracil
(5-FU) are often used to treat PDAC patients, although they only display limited antiproliferative efficacy for this disease [95]. We determined if reduction of the reserve
MCM complexes could hypersensitize the PDAC tumor lines Panc1 and Colo-357 to the
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anti-proliferative effects of gemcitabine and/or 5-FU, used clinically to manage these
cancers.
Several studies have indicated that there is a 3-10X excess of MCM complexes
loaded onto chromatin than are needed for a normal progress in S phase, which
indicates that 70-90% of the total MCMs act as back-ups in the form of dormant origins
[15, 17, 45]. Reducing the level of a single MCM subunit beyond the reserve level
causes a severe reduction in the ability of mammalian cells to proliferate [45], consistent
with the fact that all six MCM genes are essential for yeast viability [114-116]. In this
study we wanted to cause a partial knockdown of the reserve MCM complexes, while
leaving enough MCM complexes present for a normal S phase to occur and leave cell
proliferation unaffected. We tried using the manufacturers recommended 200nM
concentration of siRNA against Mcm7, but this caused a severe loss of Mcm7 protein
beyond the reserve levels and lead to suppression of cell growth (data not shown). We
titrated down the level of siRNA and found that concentrations between 1-100nM
produced partial reductions in Mcm7 or Mcm4 ranging from 70-95% reductions, which
did not affect cell growth on its own and was consistent with the loss of only the reserve
complement of MCMs. Figure 2.1A shows that siRNA treatment of 3nM against Mcm7
reduces the total Mcm7 protein level to ~30% of the normal level in Panc1 cells. To
establish the level of knockdown we used immunoblotting to compare the Mcm7 protein
level following 72 hrs of siRNA treatment to serially titrated dilutions of untreated Panc1
whole cell lysates. The reduction of 70% of Mcm7 in Panc1 cells indicates that we have
significantly suppressed the reserve MCM complement.
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Figure 2.1: Depletion of Reserve MCM Complexes Through Mcm7 Reduction
Sensitizes Panc1 PDAC Cells to Gemcitabine and 5-Fluorouracil.
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Figure 2.1 (continued). In all panels, the Panc1 tumor cell line was used. (A)
Immunoblot of serially titrated non-transfected total cell extract to the amounts indicated,
to compare siRNA against Mcm7 (3 nmol/L) level. si-treatment was for 72 hours, and
showed a reduction to 30% of the normal Mcm7 level. (B) Immunoblot of siRNA against
Mcm4 or Mcm7 showed reduction of total protein levels and chromatin-bound levels of
both Mcm4 and Mcm7. Actin and Orc4 are loading controls. (C) Diagram showing
experimental strategy for cell proliferation assays in the rest of the study. (D)
Immunoblot to show partial reduction in Mcm7 levels 72-120hrs after siRNA treatment
and during the drug treatment in panels (E-H). (E) Cell proliferation assay in cells with
Mcm7 partially depleted and treated with aphidicolin. si-Mcm7 treatment did not affect
proliferative capacity alone, but in combination with aphidicolin treatment caused
significant sensitization. Three fields in duplicate plates were counted for each
condition, the results averaged ± 1 S.D. For statistics, * = P ≤ 0.05, ** = P ≤ 0.01. (F)
Representative fields from (E), note that si-Control and si-Mcm7 treatment in the
absence of drug shows similar colony size and number. (G) Cell proliferation assay
showing chemosensitization of cells to gemcitabine treatment in the presence of cosuppression of Mcm7. Three fields in duplicate plates were counted for each condition,
the results averaged ± 1 S.D. (H) Cell proliferation assay showing chemosensitization of
cells to 5-FU treatment in the presence of co-suppression of Mcm7. Three fields in
duplicate plates were counted for each condition, the results averaged ± 1 S.D.

The MCM complex acts as a hexamer for replicative helicase functionality, and
by reducing a single MCM subunit by siRNA targeting, the whole complex is reduced on
chromatin, and thus the reserve complement is depleted [15, 23, 45, 102]. Cells also
appear to have a sensing mechanism that maintains the MCM subunits in equal
stoichiometry to each other [17, 45]. We confirmed this was the case in Panc1 cells in
which partial siRNA-mediated reduction of either Mcm7 or Mcm4 lead to a partial
reduction in the other subunit (Figure 2.1B, top). Partial reduction of Mcm7 or Mcm4
also results in both subunits being depleted on chromatin, indicating that suppression of
a single MCM subunit causes a partial reduction of the whole MCM hexamer on
chromatin (Figure 2.1B, bottom).
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We next looked at whether partial depletion of Mcm7 (and thus the reserve MCM
complement) in Panc1 cells could be used to sensitize them to replication inhibiting
drugs. Importantly, we did not want the depletion of the MCM complexes to be
detrimental to proliferative capacity on its own. We performed cell proliferation
(clonogenic) assays to assess the ability of Panc1 cells to survive and form colonies in
the presence of partial Mcm7 reductions and concurrent treatment with replicative
stress-generating drugs. Panc1 cells were transfected with 3nM of siRNA against Mcm7
or control (Figure 2.1C). The knockdown of Mcm7 was achieved by 24 hrs and
persisted as long as 120 hrs. For the cell proliferation assays, cells were transfected
with siRNA and after 48 hrs were transferred to dishes at a lower density. At 72 hrs,
Panc1 cells were treated with various levels of drugs for 2 days, then allowed to culture
for the remainder of two weeks. Cells were then fixed, stained, and the colonies were
counted for each condition. We conducted immunoblotting to verify that Mcm7 was
depleted by siRNA during the period of drug treatment with replicative stressors, 72-120
hrs (Figure 2.1D).
To relate our work to previously published studies that used aphidicolin to
suppress DNA replication we conducted clonogenic assays in Panc1 cells with
suppressed Mcm7 levels [15, 45]. We found that Panc1 cells were significantly
sensitized to the anti-proliferative effects of aphidicolin via suppression of the reserve
MCM complexes through Mcm7 targeting (Figure 2.1E). Targeting of Mcm7 alone did
not affect proliferative capacity in the absence of replicative stress. Figure 2.1F shows
example fields for 0.5 µM aphidicolin exposure +/- siRNA against Mcm7 or control
siRNA. Using the same experimental strategy we asked whether we could see a similar
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hypersensitization to clinically relevant compounds used in the management of PDAC
cancers. We tested our approach using both gemcitabine and 5-FU exposure during cosuppression of the reserve MCM complexes. In both cases, co-suppression of the
excess back-up MCM complement alongside drug exposure increased the antiproliferative effects of the chemotherapy drugs (Figure 2.1G&H). Of particular interest is
that co-suppression of the reserve MCM complexes with 5 µM gemcitabine treatment
reduced proliferative capacity of the population more than gemcitabine alone at double
the dose of 10 µM (Figure 2.1G). This would help reduce the toxic side effects of high
chemotherapeutic drug doses.
To confirm and validate the above findings, we next checked whether coreduction of a different MCM subunit, Mcm4, could also chemosensitize Panc1 cells to
5-FU. We achieved the same protein knockdown with Mcm4 as we did with Mcm7, 3nM
of si-Mcm4 caused a 70% reduction in the total protein level. We established this
through comparing the level of Mcm4 knockdown after 72 hrs of siRNA treatment to that
of serially titrated non-transfected Panc1 whole cell extract (Figure 2.2A). Our
experimental strategy for the cell proliferation assays was similar to that described
above for Mcm7 (Figure 2.2B). Immunoblotting verified that partial Mcm4 knockdown
was achieved in Panc1 lysates at 72 hrs and 120 hrs, the time span these cells were
exposed to 5-FU exposure (Figure 2.2C). Reduction of Mcm4 alone did not adversely
affect proliferative capacity, as was seen with Mcm7 depletion, however, suppression of
Mcm4 in the presence of 5-FU caused a significant sensitizing effect (Figure 2.2D).
Representative fields for the conditions of 2 µM 5-FU exposure +/- siRNA against Mcm4
or control siRNA are shown in Figure 2.2E. We conclude from these experiments that
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Figure 2.2: Depletion of Reserve MCM Complexes Through Mcm4 Reduction
Sensitizes Panc1 PDAC Cells to 5-Fluorouracil. (A) Immunoblot of serially titrated
non-transfected total cell extract to the amounts indicated, to compare siRNA against
Mcm4 (3 nmol/L) level. si-treatment was for 72 hours, and showed a reduction to 30%
of the normal Mcm4 level. (B) Diagram showing experimental strategy for cell
proliferation assays.
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Figure 2.2 (continued). (C) Immunoblot to show partial reduction in Mcm4 levels 72120hrs after siRNA treatment and during the drug treatment in panels (D&E). (D) Cell
proliferation assay in cells with Mcm4 partially depleted and treated with 5-FU. si-Mcm4
treatment did not affect proliferative capacity alone, but in combination with 5-FU
treatment caused significant sensitization. Three fields in duplicate plates were counted
for each condition, the results averaged ± 1 S.D. (E) Representative fields from (D),
showing sensitization to 2 µmol/L 5-FU with si-Mcm4 knockdown. si-Control and siMcm4 treatment in the absence of drug shows similar colony size and number.

co-suppression of the back-up MCM complement by reduction of Mcm7 or Mcm4 during
exposure to gemcitabine or 5-FU chemosensitizes Panc1 PDAC tumor cells to the antiproliferative effects of both drugs. This provides a novel strategy for increasing the
therapeutic index of existing chemotherapy drugs.

Depletion of Reserve MCM Complexes Sensitizes Colo-357 PDAC Cells to 5-FU
We wanted to confirm that the results we saw in Panc1 cells were not cell-type
specific and could also be observed in a different PDAC tumor cell line. We used the
cell line Colo-357 and conducted cell proliferation assays in which the Mcm7 subunit
was partially suppressed to the same level as had been in the Panc1 cell line (a 70%
protein reduction, data not shown) concurrently with 5-FU treatment (Figure 2.3A). The
partial depletion of Mcm7 was verified during the time of drug treatment, from 72-120hrs
(Figure 2.3B), effectively removing the reserve MCM complexes. Proliferative capacity
of Colo-357 cells was unaffected by partial suppression of Mcm7 in the absence of
replicative stress (Figure 2.3C). However, co-suppression of Mcm7 in conjunction with
5-FU exposure resulted in a significant sensitization of the cell population to the
replicative stress drug (Figure 2.3C). Representative fields for the dose of 5 µM 5-FU
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Figure 2.3: Depletion of Reserve MCM Complexes Sensitizes Colo-357 PDAC
Cells to 5-FU. (A) Experimental design for cell proliferation assays. (B) Immunoblot
verifying partial Mcm7 knockdown in Colo-357 PDAC cell line during the period of drug
treatment, 72 hr and 120hr, with 3nmol/L siRNA. (C) Results of cell proliferation assay
showing loss of Mcm7 sensitizes Colo-357 cells to 5-FU. si-Mcm7 treatment alone did
not affect cellular proliferation. Mcm7 depletion in combination with 5-FU exposure
causes significant sensitization. (D) Example fields from (C) showing si-Mcm7 or siControl treatment alone did not affect colony size and number, but si-Mcm7 treatment
with 5µM 5-FU caused loss of colony number and smaller colony size.

with or without siRNA against Mcm7 or control siRNA are shown in Figure 2.3D.
Unfortunately and unexpectedly, the Colo-357 cell line was resistant to the anti-
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proliferative effects of gemcitabine, so we were unable to assess the effects of MCM cosuppression with gemcitabine in these tumor cells. We conclude from these
experiments that Colo-357 PDAC tumor cells can also be chemosensitized to 5-FU
exposure in the background of co-suppression of the reserve MCM complement.

Depletion of Reserve MCM Complexes Suppresses Recovery of DNA Replication
Following Chemotherapy Treatment
We sought to determine how loss of reserve MCM complexes causes loss of
proliferative capacity in PDAC cells exposed to gemcitabine. Other studies have shown
that co-suppression of MCM complexes in HeLa and U2OS cells exposed to aphidicolin
or HU show evidence of checkpoint activation and DNA damage responses. This was
evident from increased levels of Chk1 and Chk2 activation, H2AX phosphorylation, or
p53 phosphorylation, all of which have been associated with replication fork stress [15,
45]. We attempted to detect similar changes indicating DNA damage and fork stress in
our PDAC cell lines using multiple levels of MCM depletion, replicative stress drug
doses, and timing of drug exposures and MCM co-suppressions. However, we were
unable to detect changes in Chk1, p53, p53-p, H2AX-p, or the BLM protein, a fork
stress responder [43]. Similar results were obtained by others in U2OS cells, where
Chk1 activation and H2AX-p changes are not observed even though p53 is altered upon
MCM loss and HU exposure [15]. It has been demonstrated that certain cancer cells are
defective in their ATR-mediated sensing mechanisms for the ability to detect DNA
damage and fork stress, causing a sensitization of such cells to functional MCM loss in
the absence of replicative stress [117]. This indicates that tumor cells may respond
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differentially to co-suppression of MCM complexes in combination with drug treatment,
which depends on the presence or absence of sensor pathways that ultimately cause
indicators of replication stress through fork stalling and DNA damage.
Although we did not observe any biochemical indicators of replication fork stress,
we hypothesized that PDAC cells with reduced MCM levels could still be having
problems in recovering DNA replication after gemcitabine exposure. We reasoned this
because reserve MCM complexes have been shown to be required for dormant origin
activation during replicative stress by single-fiber DNA strand analyses [15, 45]. We
designed an experiment in which Mcm4 or Mcm7 were partially depleted in Panc1 cells
for 72 hrs, were then treated acutely with gemcitabine for 6 hrs, the drug was then
removed and the DNA replication rates were measured every hour for the next 4 hrs
(Figure 2.4A). We verified partial Mcm4 and Mcm7 suppression by immunoblotting
(Figure 2.4B). Partial suppression of Mcm7 for 72 hrs in the absence of drug did not
reduce the base levels of DNA replication, as measured by tritiated-thymidine
incorporation (Figure 2.4C). This is consistent with idea that the reserve MCM
complexes are not required for ongoing DNA replication in an unperturbed situation,
rather, they function as back-ups. However, following exposure to gemcitabine for 6 hrs
and subsequent removal, Panc1 cells with depleted Mcm7 (Figure 2.4D) or Mcm4
(Figure 2.4E) suffered significant reduction in DNA replication as measured through
tritiated-thymidine incorporation. Interestingly, although the total amounts of DNA
replication were reduced by MCM suppression, the slope of the curves are similar,
suggesting that existing replication forks were likely progressing at similar rates, but that
there were fewer overall forks in the cells. This is consistent with previous studies that
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Figure 2.4: Depletion of Reserve MCM Complexes Suppresses Recovery of DNA
Replication Following Chemotherapy Treatment. Panc1 cells used in panels (A-E).
(A) Experimental design showing si-Mcm7 or si-Control treatment followed 72 hrs later
by an acute gemcitabine treatment for 6 hrs, and then sequential measurements of DNA
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Figure 2.4 (continued) replication activity over the next 4 hrs. (B) Immunoblots showing
partial reduction of Mcm4 and Mcm7 at 72 hrs, the time of gemcitabine treatment. (C)
The basal DNA replication rates prior to gemcitabine exposure in non-transfected, siControl and si-Mcm7 treated cells at 72 hrs. Tritiated thymidine pulse for 30 mins,
analyzed via scintillation counting, triplicate wells for each condition, averaged ± 1 S.D.
(D) Partial suppression of Mcm7, no transfection or si-Control DNA replication rates
measured via tritiated thymidine pulses at indicated times after 100nmol/L gemcitabine
exposure for 6 hrs. Triplicate wells for each condition, averaged ± 1 S.D. (E) Partial
suppression of Mcm4, no transfection or si-Control DNA replication rates measured via
tritiated thymidine pulses at indicated times after 100nmol/L gemcitabine exposure for 6
hrs. Triplicate wells for each condition, averaged ± 1 S.D.

demonstrated loss of MCM complexes blocks activation of dormant origins on DNA fiber
analysis [15, 45]. We conclude that PDAC cells exposed to gemcitabine are debilitated
in their ability to recover DNA replication under conditions of reserve MCM suppression.

Tumor Cells are Differentially Sensitized to Reserve MCM Complex Loss During
Gemcitabine Exposure than Nontransformed Cells
It has been indicated that tumor cells respond differentially to MCM depletion
than normal, untransformed cells. Through overexpression of geminin, an inhibitor of
MCM loading, Mcm2 levels were decreased on chromatin in U2OS and Saos2 tumor
and normal primary cells lines, and normal cells appeared to sense the lack of sufficient
MCM complexes and arrested in G1 phase with no apoptosis, whereas tumor cells
progressed into a unsuccessful S phase, arrested and apoptosed [118]. We determined
whether under our conditions of partial Mcm7 depletion, which does not affect cellular
proliferation, we could see differential sensitivity to gemcitabine between Panc1 cells,
and an immortalized and non-tumor derived cell line called HaCaT [112, 119]. We
wanted to compare PDAC cells to this highly proliferative, non-transformed epithelial
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Figure 2.5: Tumor Cells are Differentially Sensitized to Reserve MCM Complex
Loss During Gemcitabine Exposure than Nontransformed Cells. (A) Immunoblot
showing partial Mcm7 reduction in Panc1 cells following 3nmol/L siRNA for 72 hrs and
120 hrs. (B) Immunoblot showing partial Mcm7 reduction in HaCaT cells following
3nmol/L siRNA for 72 hrs and 120 hrs. (C) Cell proliferation assays in Panc1 cells with
partial Mcm7 suppression and the indicated doses of gemcitabine. Significant
sensitization to drug was seen with Mcm7 co-suppression. (D) Cell proliferation assays
in HaCaT cells with partial Mcm7 suppression and the indicated doses of gemcitabine.
No sensitization to drug seen with Mcm7 co-suppression. For panels (C-D) three fields
in duplicate plates were counted and averaged ± 1 S.D.
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cell type to remove any bias due to slow-proliferating issues (such as with primary
cells), and because chemotherapeutic agents tend to cause adverse side effects
epithelial cells in patients. We performed cell proliferation assays as before, and verified
that Mcm7 protein levels were partially and similarly depleted in both Panc1 (Figure
2.5A) and HaCaT (Figure 2.5B) during the 72-120 hrs time period of gemcitabine
treatment. We determined that Panc1 cells were significantly sensitized to the
gemcitabine doses tested (Figure 2.5C) when MCM complexes were co-suppressed,
however, at the same gemcitabine doses and same level of MCM suppression, HaCaT
cells were not sensitized (Figure 2.5D). This suggests that suppression of MCM function
might provide differential sensitivity of tumor cells to exposure with replicative stress
drugs, while leaving normal cells relatively unaffected. This would be of benefit to
patients, as an anti-MCM drug in conjunction with chemotherapy treatment would show
anti-tumorigenic activity, but would not cause adverse side effects to normal, epithelial
cells.

Depletion of Reserve MCM Complexes Chemosensitizes Colon Carcinoma Cells
to Oxaliplatin and Etoposide
To establish whether our results extended beyond PDAC cancers into other
cancer type, we utilized a colorectal cell line to determine whether co-suppression of
MCMs causes chemosensitization. We tested SW480 colon carcinoma cells in the
presence or absence of partial MCM suppression for their sensitivity to the two
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chemotherapeutic drugs oxaliplatin and etoposide that have been used to treat
colorectal cancer, but produce toxic side effects which reduce their indication for patient
use. Both oxaliplatin and etoposide are indirect replication fork blocking drugs,
oxaliplatin is a DNA crosslinking agent and etoposide is a topoisomerase inhibitor. We
partially depleted Mcm7 by siRNA treatment for 72 hrs to approximately 30% of its
normal levels in SW480 cells (Figure 2.6A). We performed cell proliferation assays as
outlined (Figure 2.6B) and verified that Mcm7 was partially reduced during the 72-120 hr
drug exposure time (Figure 2.6C). Exposure of SW480 cells to oxaliplatin or etoposide
with partial MCM co-suppression significantly reduced the proliferative capacity of the
colorectal tumor population at the indicated doses (Figure 2.6D&E).
We next determined if exposure to oxaliplatin or etoposide with co-suppression of
MCM complexes caused an increase in the apoptotic index of the SW480 cells. We
partially co-suppressed Mcm7 with siRNA for 72 hrs, and added either drug during the
last 48 hrs, followed by the analysis of apoptotic index using Annexin-V staining and
flow cytometry (Figure 2.6F). Reduction of Mcm7 protein occurred from 24-72 hrs (data
not shown, but 72 hrs shown in Figure 2.6G). Treatment with both control and Mcm7
siRNA in the absence of chemotherapy drug produced a slight increase in apoptotic
levels of the SW480 population (Figure 2.6H&I). However, exposure to oxaliplatin
(Figure 2.6H) or etoposide (Figure 2.6I) in the background of partially reduced MCM
complexes caused a significant sensitization to both drugs, resulting in higher apoptotic
indices compared to no siRNA or si-Control treatment. Importantly, co-suppression of
MCM complexes almost doubled the anti-proliferative effects of both oxaliplatin and
etoposide at the highest concentrations tested (Figure 2.6H&I). Our conclusion from
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Figure 2.6: Depletion of Reserve MCM Complexes Chemosensitizes Colon
Carcinoma Cells to Oxaliplatin and Etoposide.
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Figure 2.6 (continued). The colorectal cell line SW480 was used in panels (A-I). (A)
Immunoblot of serially titrated non-transfected total cell extract to the amounts indicated,
to compare siRNA against Mcm7 (1 nmol/L) level. si-treatment was for 72 hours, and
showed a reduction to 30% of the normal Mcm7 level. (B) Diagram showing
experimental strategy for cell proliferation assays in panels (C-E). (C) Immunoblot to
show partial reduction in Mcm7 levels 72-120hrs after siRNA treatment and during the
drug treatment. (D) Cell proliferation assay in cells with Mcm7 partially depleted and
treated with the indicated doses of oxaliplatin. si-Mcm7 treatment did not affect
proliferative capacity alone, but in combination with oxaliplatin treatment caused
significant sensitization. Three fields in duplicate plates were counted for each
condition, the results averaged ± 1 S.D. (E) Cell proliferation assay in cells with Mcm7
partially depleted and treated with the indicated doses of etoposide. si-Mcm7 treatment
did not affect proliferative capacity alone, but in combination with oxaliplatin treatment
caused significant sensitization. Three fields in duplicate plates were counted for each
condition, the results averaged ± 1 S.D. (F) Systematic for the apoptosis assays in
panels (G-I). (G) Immunoblot showing partial Mcm7 depletion at time of apoptosis
assay, 72 hrs post-transfection. (H) Apoptosis assay using annexin V staining and flow
cytometry to measure apoptotic index of cells with partial Mcm7 depletion treated with
oxaliplatin at 10µmol/L. Conducted in duplicate, averaged ± 1 S.D. (I) Apoptosis assay
using annexin V staining and flow cytometry to measure apoptotic index of cells with
partial Mcm7 depletion treated with etoposide at 10 and 15 µmol/L. Conducted in
duplicate, averaged ± 1 S.D.

these experiments is that co-suppression of MCM complexes also chemosensitizes
colorectal carcinoma cells to the anti-proliferative effects of oxaliplatin and etoposide,
similar to what we observed in PDAC cells with gemcitabine and 5-FU treatment.

Discussion

We provide here definitive evidence that depletion of the reserve MCM
complexes causes chemosensitization of multiple human tumor cell types to several
chemotherapeutic drugs used in the clinical management of human cancer. Partial
suppression of MCM complexes utilizing siRNA against Mcm4 or Mcm7 causes PDAC
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tumor cell lines to increase their sensitivity to the anti-tumor effects of both gemcitabine
and 5-FU. We observed a similar effect in a colorectal tumor cell line treated with
oxaliplatin or etoposide in the background of co-suppression of the MCM complexes.
The chemotherapeutic agents tested act directly or indirectly to block DNA replication
fork activity, and prior studies have suggested that reserve MCM complexes are
necessary to recover replication following drug exposure that causes replicative stress
[15, 45]. The prior studies that identified that MCM suppression could chemosensitize
cells primarily used aphidicolin or hydroxyurea, which are not clinically relevant drugs
[15, 45]. We have extended this important concept by testing clinically relevant drugs in
cancer cell lines that recapitulate the cancers these drugs are used to treat. We
demonstrated that following acute gemcitabine exposure, PDAC cells required reserve
MCM complexes to recover DNA replication (see our model in Figure 2.7). Interestingly,
PDAC cells were more sensitive to MCM depletion following gemcitabine exposure than
a non-transformed epithelial cell line, suggesting that co-targeting MCM complexes
during chemotherapy regiments will provide a selective anti-tumor advantage.
Our work has important implications for the treatment of cancer patients, by
potentially increasing the therapeutic efficacy of existing chemotherapy drugs used in
PDAC management that are not currently very effective on their own by co-suppressing
reserve MCM functions [95]. Colorectal cancer treatment often involves the use of
oxaliplatin in chemotherapy, which has been associated with neuropathy that limits the
ability to treat patients with this drug [108, 109]. Colorectal and other cancer are often
treated with etoposide, but this compound is known to produce toxic cardiac side effects
many years after clinical exposure that limit its utility [110, 111]. Our study suggests that
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Figure 2.7: Model of how Depletion of Reserve MCM Complex Causes
Chemosensitivity. Depletion of MCM protein levels leads to a reduction in the level of
reserve MCM complexes loaded onto chromatin. When replication forks stall in S phase
due to the replicative stresses provided indirectly by chemotherapeutic agents, the lack
of reserve MCM complexes causes fewer CMG helicases to be activated to recover
DNA replication, leading to incomplete replication and the induction of apoptosis.

the development and use of anti-MCM drugs in combination with these and similar
chemotherapeutic compounds has the potential to increase the therapeutic index of
existing clinical compounds. This could allow for the reduced administration of toxic
chemotherapy drugs such as oxaliplatin or etoposide that could reduce the toxic side
effects associated with these compounds. The clinical utility of anti-MCM drugs is clear,
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however, targeting MCMs over sustained periods should be avoided as partial MCM
suppression can result in genomic instability and increased DNA damage [15, 45, 117],
and mice with sustained depleted MCM complexes on chromatin display increased
cancer risk [43]. As such, sustained MCM suppression during chemotherapeutic
regimens may be contraindicated for the clinical management of cancer, but shorter
durations of MCM co-suppression may overcome these difficulties and allow anti-MCM
drug use for cancer treatment. As an alternative approach, chemotherapy treatments
alternating with shorter anti-MCM drug treatment may be more effective and less likely
to produce DNA damage in non-tumor cells.
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CHAPTER THREE:
C-MYC REGULATION OF CMG HELICASE ASSEMBLY AND ACTIVATION
THROUGH CHROMATIN DECONDENSATION AND CDC45 LOCALIZATION

Abstract

The oncogene c-MYC is essential for cellular proliferation and growth. c-Myc is
overexpressed in many human cancers, and part of its oncogenic effects is due to a
non-transcriptional role in control over the initiation of DNA replication. Myc
overexpression leads to over-activation of DNA replication origins, causing DNA
damage. Activation of replication origins requires the assembly of the replicative Cdc45MCM-GINS (CMG) helicase that unwinds DNA. When overexpressed, Myc binds to
intergenic regions of the genome where DNA replication origins are found. We
demonstrate here that the mechanism behind how Myc promotes CMG helicase
assembly and activation is through dramatic chromatin decondensation of higher order
chromatin. This depends on the presence of the Myc-Box II domain, which is critical for
Myc-oncogenic transformation. Myc-induced chromatin decondensation does not affect
MCM assembly, however, it causes recruitment of Cdc45 and GINS to form active
replicative helicases. Recruitment of the histone acetyltransferases GCN5 and Tip60 to
chromatin via the Myc-box II domain is required for chromatin unfolding. Finally, normal
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levels of Myc in late-G1 phase also regulate Cdc45 recruitment to the CMG helicase.
These findings identify a previously unknown role for Myc in normal cell cycle
progression through regulating DNA replication initiation and provide a new mechanistic
explanation for Myc driven oncogenic transformation.

Introduction

The proto-oncogene c-MYC is essential for cellular proliferation, cell cycle
progression and is one of the most commonly amplified genes in cancer [120]. c-Myc
(Myc) is in a family of basic helix-loop-helix leucine zipper (bHLH-LZ) transcription
factors (including N- and L-Myc) that are deregulated in a variety of tumors [66, 121].
Excessive Myc protein levels generate DNA replication stress, damage and genomic
instability in only 1-2 cell cycles, likely contributing to tumorigenesis [14, 76]. Myc
functions in complexes with other proteins such as Max to regulate transcription [121].
Myc activates and represses a set of direct target genes by binding to DNA elements
called consensus E-boxes (CACGTG) in the promoters of these genes [63, 64].
However, the maximum Myc-induced gene expression is less than two-fold, which does
not adequately explain all of the potent effects Myc has on cell cycle progression [66,
68, 69]. Myc is commonly studied for its transcriptional roles, but there are a number of
unexplained findings regarding Myc that distinguish it from other basic transcription
factors and suggest that the mechanistic role of Myc in oncogenesis may extend
beyond transcriptional control.
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Myc binds to widespread areas of chromatin, and several array projects have
shown evidence for Myc binding to over 25,000 genomic loci, which is in stark contrast
with other transcription factors [122-124]. Approximately 40% of these sites are greater
than 10kb from promoters [122]. More recent studies using genome-wide chromatin
immunoprecipitation have shown that the number of Myc binding sites progressively
increases from a non-Myc amplified (control) state, through Myc amplified pre-tumor
and tumor formation [63]. While two-thirds of Myc binding sites in the control state are in
proximity to promoters, the majority of new Myc binding sites in the Myc overexpressed
pre-tumor and tumor states are distal, resulting in equal intra- and intergenic binding loci
[63]. Overexpressed Myc binds increasingly to non-E-box sites or non-consensus Eboxes (CANNTG) [64, 84, 124, 125]. The mechanisms by which Myc functions to
influence oncogenesis through large-scale chromatin binding are unknown. Myc is
known to have a non-transcriptional role in the initiation of DNA replication, although the
mechanism is poorly understood [14]. The intergenic regions where Myc binds are also
the location of replication origins [13].
Initiation of DNA replication begins with the activation of the replicative helicase,
which unwinds DNA and marks the G1-S transition [28, 126]. The helicase forms on a
precursor protein complex called the pre-Replication Complex (pre-RC) [12]. Pre-RCs
are composed of the Origin Recognition Complex (ORC), which binds to future origins
of replication and recruits Cdc6 and Cdt1 proteins that load the Mini-Chromosome
Maintenance (MCM) 2-7 complex [127-132]. Excess MCM complexes are loaded onto
chromatin in a distributed manner throughout intergenic regions, beyond the number
required for a normal S phase, and function as reserves in S phase during DNA
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replication stress [15, 44]. Myc has been shown to bind to replication origins and is
found in complexes with pre-RC proteins [14, 84]. Certain MCM complexes are chosen
to become replicative CMG (Cdc45, MCM, and GINS) helicases through the recruitment
of the Cdc45 and the GINS (go-ichi-nii-san) protein complex [133]. The MCM
complexes provide the ATPase activity necessary for the CMG helicase to unwind DNA
at the G1-S transition prompting the initiation of DNA replication from replisomes
composed of CMG helicases and DNA polymerases [28, 134-136]. This activation
minimally requires Cyclin A-Cdk2 and Dbf4-Cdc7 activity [136]. Cdc45 protein levels are
extremely low in cells relative to the MCM complex, and its recruitment is rate limiting
for helicase formation and activation [17]. In transcriptionally inert embryonic Xenopus
extracts, maternally-supplied Myc is imported into the nucleus and is required for DNA
replication [73]. This suggests that Myc has a non-transcriptional role in DNA
replication. Overexpressed Myc causes increased origin activity and DNA damage in
both mammalian cells and Xenopus extracts, which depends on the presence of Cdc45
and GINS [14, 78]. However, the mechanism by which Myc promotes CMG helicase
activation has yet to be demonstrated.
Myc induced oncogenic transformation and replication origin activity is dependent
on a highly conserved N-terminal Myc domain called Myc-box II (MBII) [61, 74, 75, 137].
Myc associates with a nuclear cofactor called TRRAP through the MBII domain, which
then recruits the histone acetyltransferases (HATs) GCN5 or Tip60 to chromatin to
mediate the acetylation of histone tails, resulting in open chromatin and transcriptional
activation [85, 87, 88]. Loss of Myc has been shown to produce global nuclear
chromatin condensation and histone modifications associated with an inactive
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chromatin state [83]. Myc binds to chromatin that is enriched in acetylated and
methylated histones H3 and H4, and then promotes further histone H4 acetylation
associated with open chromatin [81, 82, 138, 139]. These findings are not typical of
classical transcription factors and strongly suggest that Myc is unique and likely
functions in a broader chromatin regulatory manner that extends beyond transcriptional
control of target genes. However, the effect Myc-induced modification of chromatin has
on DNA replication has yet to be determined.
Here we show that the mechanism by which Myc causes initiation of DNA
replication involves stimulating dramatic chromatin decondensation, allowing CMG
helicases to fully assemble on the pre-loaded chromatin bound MCM complexes
through localization of the rate-limiting Cdc45 molecule. The helicases become
functional, and result in active replication origins. We further show that chromatin
decondensation is dependent on Myc-mediated recruitment of the HATs GCN5 and
Tip60 to chromatin via the MBII domain, and requires histone H4 tail modifications to
occur. Depletion of endogenous Myc causes a reduction in chromatin-bound Cdc45
protein levels and S phase entry, which can be rescued by Myc overexpression, but is
dependent on the MBII domain presence. These findings identify a previously unknown
role for Myc in normal cell cycle progression whereby DNA replication initiation is
regulated through the assembly and activation of CMG helicases on Myc-mediated
open chromatin regions. Our results also provide new mechanistic insight into Myc
oncogenic transformation in which overstimulation of DNA replication could result in
genomic instability and carcinogenesis.
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Materials and Methods

Cell Culture, Synchronizations and Transfections
Mouse keratinocytes (Balb/MK) were maintained in low calcium MEM
supplemented with 8% dialyzed FBS (Hyclone) and 4ng/ml EGF (Invitrogen). The
retroviral packaging cells lines psi-2 3T3 and PA317 and the BT-549 cell line were
maintained in phenol-free DMEM supplemented with 10% FBS (Hyclone). The CHO cell
line (clone A03_1) was maintained in DMEM supplemented with 10% FC2 and 0.3µM
methotrexate.
To create the MK and BT-549 MycER/ΔMycER cell lines, the psi-2 3T3 cell lines
was transfected with pMV7-MycER/ΔMycER plasmids using polyethylenimine (PEI) and
selected with 400µg/mL G418 (Invitrogen) for two weeks. Dense cells were then fed
fresh media containing no G418 for 24 hours, after which the virus-containing media
was removed, filtered, polybrene added, and placed onto PA317 cells at 50% density.
After 48 hours, these cells were selected with 400µg/mL G418, although little cell death
occurred due to high infection rate. After two weeks of selection, dense cells were then
fed fresh media containing no G418 for 24 hours, after which the virus-containing media
was removed, filtered, polybrene added, and used to infect MK or BT-549 cells at 50%
density. MK cells were selected with 50µg/mL G418 for two weeks and then maintained
in 25µg/mL G418 phenol-free media with charcoal-stripped serum. BT-549 cells were
selected with 100µg/mL G418 for two weeks and then maintained in 50µg/mL G418
phenol-free media with charcoal-stripped serum.
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MK MycER/ΔMycER cells were synchronized by EGF deprivation for 3.5 days
and stimulated to enter the cell cycle by the re-addition of EGF, with or without
MycER/ΔMycER induction using 2µM 4-hydroxytamoxifen (Sigma) at the indicated
times. CHO transfections were performed for 24 hrs with TransIT-LT1 (Mirus) as per
manufacturers recommendations. MK siRNA transfections were performed following the
manufacturers recommendations using Dharmafect 4 transfection reagent, siRNA
concentrations used were 100nM of siLuciferase or siGenome mouse Myc
(Dharmacon).

Plasmids
pMV7-MycER/ΔMycER were provided by M. Eilers [74]. LacI-Myc and LacI-ΔMyc
were sub-cloned into the LacI vector from the pMV7-MycER/ΔMycER plasmids. LacIVP16 was provided by A. Belmont (University of Illinois). HsCdt1 and HsBRCA1 (6c-w)
were expressed using pRcLac [140]. Set8-DBD was generated by proofreading PCR
and expressed using pcDNA3-HA-NLS [140]. E. Seto (Moffitt Cancer Center) supplied
pIRES GCN5 (WT), pIRES GCN5 (GYG-AYA mutant), which were subsequently
subcloned into pcDNA3-HA vector, pcDNA3-Flag Tip60 (WT) and pcDNA3-Flag Tip60
(GQE mutant) [141].

Antibodies
Rabbit polyclonal antibodies unless otherwise stated; anti-Psf2, anti-HBO1, antiGCN5, anti-Tip60, mouse monoclonal (mAb) anti-ER, mAb anti-Mcm7 (Santa Cruz
Biotechnology); mAb anti-actin, mAb anti-Flag (Sigma); anti-Myc (provided by Steve
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Hann, Vanderbilt University); rat monoclonal anti-RPA32 (Cell Signaling), mAb anti-LacI
(Millipore); anti-LacI (Stratagene); mAb anti-HA (Covance); mAb anti-BrdU (Life
Technologies); chicken polyclonal anti-Cdc45 [17]; anti-Mcm2 [17]; chicken anti-Mcm4
[17].

Immunoblotting and Immunofluorescence
For immunoblots, equal cell numbers were scraped off plates into cold PBS,
lysed and boiled in 1x Laemmli loading dye (for total protein) or were separated into
Triton X-100 soluble or resistant (chromatin bound) fractions. Cells were resuspended in
buffer A (10mM HEPES pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.34 M sucrose, 10%
glycerol, 1 mM DTT, 5 µg of aprotinin per ml, 5 µg of leupeptin per ml, 0.5 µg of
pepstatin A per ml, 0.1 mM phenylmethylsulfonyl fluoride) containing 0.1% Triton X-100
for 5 mins on ice. Nuclei were isolated by low-speed centrifugation (5 min, 1,300 x g
4°C), washed in buffer A without TX-100, and then lysed in buffer B (3 mM EDTA, 0.2
mM EGTA, 1 mM DTT, and previously described protease inhibitors) for 30 mins on ice.
Insoluble chromatin was collected by low-speed centrifugation (5 min, 1,700 x g 4°C)
and resuspended in an equal volume of buffer B and 2X Laemmli loading dye.
Immunoblotting was conducted using standard procedures [17].
For IF, MK and CHO cells were grown on cover slips. Prior to fixation cells were
pre-extracted for 10 mins with cold 0.1% TX100 in PBS-pH 7.4 (5mM MgCl2, 0.1mM
EDTA-pH 8) unless otherwise stated. Cells were then fixed for 15 mins at room
temperature using 2% formaldehyde/PBS solution for CHO cells and 4%
formaldehyde/PBS solution for MK cells, followed by two 10 min PBS washes. IF
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analysis was conducted by permeabilizing cells for 5 mins in 0.2% TX-100/1% normal
donkey serum (NDS)/PBS solution at 4°C, followed by two 15 min 1%NDS/PBS
blocking-washes. Primary antibody incubation occurred in a moist chamber for 1 hour. If
a secondary antibody was used, two 15 min 1%NDS/PBS washes occurred after the
primary antibody incubation. For BrdU analysis, cells were treated with 3N HCl for 30
mins prior to primary antibody incubation, followed by three 10 min 1%NDS/PBS
washes. After the last antibody incubations, cells were washed twice with PBS solution
for 10 mins, incubated with a 0.5µg/mL DAPI/PBS solution for 5 mins to stain the nuclei,
then washed twice with PBS solution and mounted onto slides with anti-fade solution
where appropriate. Images were obtained using a Zeiss upright fluorescent microscope
(CHO cells) or a Leica confocal microscope (MK cells).

DNA Replication and Cell Proliferation Assays
DNA replication was measured by pulsing triplicate wells with 3µCi/mL of [3H]
thymidine for 30 minutes and fixing with ascorbic acid followed by scintillation analysis
of one-third of the trichloroacetic acid-precipitable material [75]. For BrdU experiments,
replicating DNA was labeled with 15µM BrdU incorporation for 30 mins, fixed and
analyzed by IF as described above. Cell proliferation (clonogenic) assays with
asynchronous MK-MycER/ΔMycER and BT-549 (MycER/ΔMycER) cell lines were
conducted in duplicate on 35mm tissue culture plates and treated with the indicated
drugs and doses for 48 hrs, then allowed to culture for the remaining 2 weeks. Cells
were fixed with an acetic acid/methanol solution, washed with methanol, and stained
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with Giemsa for 15 mins to quantify surviving colony numbers. Aphidicolin and
gemcitabine drugs were from Sigma.

Statistics
Two-tailed t tests performed throughout, **P ≤ 0.01, *P ≤ 0.05.

Results

Myc Elevation Causes an Increase in CMG Helicase Assembly and Activation
Previous studies have indicated that Myc elevation causes over-activation of
origin activity in S phase [14, 75]. We re-established a Myc overexpression system by
creating the inducible mouse keratinocyte (MK) MycER or mutant ΔMycER (missing the
MBII domain) cell lines, showed equal protein expression (Figure 3.1A) and reconfirmed
that only MK-MycER cells (Figure 3.1B) demonstrated almost a doubling of DNA
replication in early-S phase (15hr and 18hr), indicative of increased origin usage,
whereas MK-ΔMycER (Figure 3.1C) did not [75]. Activation of MycER in these cells
mimics overexpression conditions for Myc. Note that ΔMycER activation does not
appear to confer a dominant-negative effect. Increased DNA replication in the induced
MK-MycER cell line was due to more replication foci per cell (Figure 3.1D, quantified in
Figure 3.1E) rather than an increased number of cells exiting quiescence and entering S
phase.
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Figure 3.1. Myc Elevation Causes and Increase in CMG Helicase Assembly and
Activation. (A) Immunoblot (IB) probed with antibodies to indicated proteins
demonstrating the creation and equal protein expression of the MK-MycER and MKΔMycER cell lines. EGF-synchronized MK-MycER (B) and MK-ΔMycER (C) cells were
treated with 4-OHT at time of EGF re-addition (0hr) and pulsed with 3H-thymidine at
indicated times.
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Figure 3.1 (continued). (D) Synchronized MK-MycER cells were treated with 4-OHT at
0hr and pulsed with BrdU at 15hrs. Analyzed by confocal microscopy. (E) Graphical
representation of the per cell brightness of BrdU positive cells only. (F) Synchronized
MK-MycER cells treated with 4-OHT at the indicated times and pulsed with 3H-thymidine
at 0, 12 and 15hrs. (G) S phase analysis of Myc induced replication. Synchronized MKMycER cells treated with 4-OHT at 0hr and pulsed with 3H-thymidine at indicated times.
IB analysis of MK-MycER (H) and MK-ΔMycER (I) effects when activated with 4-OHT at
0hr on total protein expression and the chromatin-bound complement of indicated
proteins at 15hrs. Values in panels B, C, E, F and G are means of triplicate wells or
fields, ±1SD. Experiments conducted in duplicate or triplicate.

To dissect the mechanism by which Myc initiates DNA replication we asked when
in G1-phase Myc activation was necessary to elicit origin over-activation. MK-MycER
cells were induced at the indicated times throughout early to mid-G1 phase, and origin
activation in S phase (15hr) was seen with MycER activation up to 8hrs into G1, but not
after 10hrs (Figure 3.1F). In these quiescence-released cells the G1-S transition
occurred ~12hrs. The 8hr time period is when the MCM complexes are becoming
chromatin-bound, followed shortly after by Cdc45 recruitment to chromatin. Myc has
been shown to co-localize with BrdU foci only in early-S phase [14]. We saw that the
most dramatic Myc-induced origin activation occurred in early-to-mid S phase (1620hrs), and diminished as S phase progressed (Figure 3.1G). These results indicate
that overexpression of Myc promotes excessive DNA replication during the early half of
S phase, a time when euchromatic regions are known to be replicated.
Our results and those of others indicate that Myc-induced origin over-activation is
due to an increased number of active CMG helicases [14, 78]. To establish this we
analyzed the endogenous total and chromatin-bound proteins of Cdc45, MCM2 and
RPA. Although Myc is a transcription factor, MycER activation at the beginning of G1
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phase did not cause a change in the total protein levels of the analyzed proteins (Figure
3.1H upper panel). These proteins are functional when bound to DNA, so we assessed
their levels chromatin-bound levels in Figure 3.1H, lower panel. MycER induction
caused a dramatic increase in the chromatin-bound complement of the Cdc45 protein, a
replication-limiting factor for CMG helicase assembly and activation [17]. Only 1/3 of the
total Cdc45 protein in cells is chromatin-bound [17], and Myc appears to be promoting
the normally soluble complement of Cdc45 to become tightly associated with chromatin.
MycER induction also caused an increase in chromatin-bound RPA, an indicator of
active CMG helicases. The chromatin-bound Mcm2 protein levels did not change. It has
been established that in mammalian cells MCM complexes are loaded in a 2-3-fold
excess onto DNA [17], so Myc-induced CMG helicase over-activation would not
necessarily require additional MCM complexes to load onto chromatin. No changes in
total protein or chromatin-bound proteins levels were seen with ΔMycER activation
(Figure 3.1I). We conclude that Myc overexpression in the early to mid G1 phase
causes an increase in the number of assembled and activated CMG helicases in S
phase, which is dependent on the presence of the MBII domain.

Myc Induced Over-Activation of CMG Helicases Causes Chemosensitization
The excess MCM complexes loaded onto DNA act as tumor suppressors, by
enabling additional replication origins to activate when replication forks stall [43]. This
would require additional CMG helicases to form and activate on the reserve MCM
complexes. Our group and others have shown that reducing MCM complexes on
chromatin chemosensitizes cells to replication fork stalling drugs, due to an inability to
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recover DNA replication [44, 97]. We reasoned that by creating more CMG helicases
than is necessary for a normal S phase, as Myc elevation does, the reserve MCM
complexes are being utilized and thus depleted so will not be available to recover DNA
replication during drug treatment, which would negatively affect proliferative capacity.
The experimental design is outlined in Figure 3.2A, in which activation of MycER or
ΔMycER occurred simultaneously with a 2 day drug treatment of either Aphidicolin, a
DNA polymerase inhibitor, or Gemcitabine, a pyrimidine analogue that negatively affects
nucleotide pool levels. Both of these drugs indirectly stall replication forks, which would
then require additional CMG helicases to become active to recover replication. We
conducted colony formation assays, and in Figures 3.2B, C, D, F and G we picked a
level of MycER/ΔMycER activation that did not negatively affect cell growth alone,
although due to Myc driven over-stimulation of CMGs and consequent deficiency of
reserve MCMs would potentially sensitize these cells to fork-stalling drugs. In the MKMycER cell line, the combination of MycER activation and a low level of Aphidicolin
treatment caused a significant loss of proliferative capacity (Figure 3.2B).
Representation fields are shown in Figure 3.2C. Under the same conditions, the MKΔMycER cell line did not demonstrate a loss of proliferative capacity (Figure 3.2D). A
number of clinical studies have shown that Myc amplified tumors respond more
favorably to chemotherapy treatment than non-Myc amplified tumors, as measured by
parameters such as increased 5 year survival rates or increased remission rates [142144]. To test our hypothesis in an oncogenic situation, we created the Myc
overexpression system in a breast cancer cell line, BT-549 (Figure 3.2E), known to
have normal Myc levels and thus allowing us to observe an effect of Myc
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Figure 3.2. Myc Induced Over-Activation of CMG Helicases Causes
Chemosensitization.
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Figure 3.2 (continued). (A) Diagram showing experimental design for cell proliferation
assays. (B) MK-MycER cell proliferation assay, asynchronous cells were plated and
then treated with 1µM aphidicolin concurrently with 50nM 4-OHT for 48hrs, and then
allowed to form colonies before staining and counting. (C) Representative fields from
the experiment in (B). (D) MK-ΔMycER cell proliferation assay, as in experiment (B). (E)
IB with indicated antibodies demonstrating the creation and equal protein expression of
BT-549 (MycER) and BT-549 (ΔMycER) cell lines. Cell proliferation assay for BT-549
(MycER) (F) and BT-549 (ΔMycER) (G) using 100nM 4-OHT concurrently with 10nM
Gemcitabine. (H) MK-MycER cell proliferation assay showing significant reduction in
proliferative capacity as 4-OHT concentration increases. (I) MK-ΔMycER cell
proliferation assay showing no change in proliferative capacity as 4-OHT concentration
increases. All cell proliferation assays are means of duplicate plates, ±1SD.
Experiments were conducted in duplicate.

overexpression. We tested whether we could chemosensitize this breast cancer cell line
to Gemcitabine, a chemotherapy drug frequently used in the clinical management of
breast cancer and an indirect fork-blocking agent. As seen in Figure 3.2F, co-activation
of MycER in concurrently with Gemcitabine treatment resulted in significant sensitization
to the anti-proliferative effects of this chemotherapeutic agent. As with the MK cell line,
this effect depended on the presence of the MBII domain, as the BT-549 (ΔMycER) cell
line was not chemosensitized (Figure 3.2G). Excessive Myc alone has been reported to
cause an increase in DNA damage and activation of an ATM/ATR-Chk1 dependent
checkpoint [14]. This is suggestive that a loss of proliferative capacity may follow, so we
asked whether increasing MycER induction would cause a reduction in colony growth in
our experimental assay. As Figure 3.2H shows, as the induction of MycER increases,
colony number significantly decreases, however this was not seen following ΔMycER
induction (Figure 3.2I), showing that Myc-mediated loss of proliferative capacity is
dependent on the presence of the MBII domain. This indicates that normal noncancerous cells cannot tolerate sustained high Myc overexpression.
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We conclude that elevated Myc expression sensitizes normal and cancerous
cells to replicative stresses provided by fork-stalling drugs, consistent with the ability of
Myc to promote over-activation of CMGs from the pool of reserve MCMs necessary for
recovery from such stresses.

Myc-Targeting Induces Large-Scale Chromatin Unfolding
The association of Myc binding at sites with histone modifications related to open
and active chromatin led us to hypothesize that Myc may be promoting the assembly
and activation of CMG helicases through chromatin unfolding and increased
accessibility to the underlying DNA structure. This would also be consistent with our
findings that elevated Myc is required in early to mid G1, prior to CMG helicase
assembly, to elicit increased DNA replication. There are currently no technological
means to assess higher-order chromatin structural changes at DNA replication origins.
However, an innovative chromatin remodeling system (Figure 3.3A) utilizing a CHOderived cell line (A03_1) has been successfully used to address whether proteins can
elicit changes in chromatin state (condensed/closed, compared with
decondensed/unfolded/open), with physiologically meaningful outcomes [140, 145,
146]. This system contains an engineered 90 Mb homogenous staining region (HSR),
through the stable insertion and amplification of a Lac-operator (LacO)/DHFR vector
also containing stretches of random intergenic DNA. The final HSR contains ~1,600
such vectors across 60 amplicons, and each amplicon is composed of ~500-kb of vector
sequences adjacent to ~1-Mb of co-amplified genomic DNA [147]. Proteins of interest
are fused with a LacI-DNA binding domain (DBD), which allows them to be targeted to
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the HSR and visualized using anti-LacI antibodies. The visual appearance of the HSRs
are classified as closed (the usual unperturbed state), small open, large open (see
Figure 3.3A and B for examples) or indeterminate, as previously described [140]. This
system provides insight into regulation of higher-order chromatin dynamics that cannot
be analyzed by any other current technological means.
The chromatin remodeling that occurs in this system is due to physiologically
relevant events involved in altering chromatin structure by the targeted proteins. Other
transcription factors have been tested in this system, such as BRCA1, E2F1 and VP16,
and shown to facilitate chromatin unfolding through histone acetylation [145, 148]. A
benefit of assessing Myc in this system is that it recapitulates several known
physiological functions associate with Myc. Myc is a transcription factor that normally
binds to DNA through its C-terminus to carry out its physiological functions, and when
Myc is overexpressed as it often is in cancer, it binds to expansive non-promoter
genomic regions. Myc has never been tested in this system before, and to determine
whether Myc can promote large-scale chromatin decondensation, Myc and ΔMyc were
fused to LacI and transfected into the CHO (A03_1) cell line. As controls, LacI-BRCA1
(6c-w), LacI-VP16 and LacI-DBD alone were expressed and assessed. Figure 3.3B
shows example HSRs from the controls, showing the expected results that LacI-DBD
elicits no changes to the HSRs; they remain a small-condensed dot. LacI-BRCA1 (6c-w)
HSRs are mostly open (quantified in Figure 3.3D), and herein referred to as small
HSRs, consistent with previous findings [145]. LacI-VP16 targeting caused a large
chromatin decondensation event as previously reported (Figure 3.3B) [148]. Targeting
Myc to the HSRs resulted in a massive chromatin decondensation event (Figure 3.3C),
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to the extent that Dapi staining in the HSR region was barely apparent due to the very
low density of DNA in the center of the large decondensed ‘halos’. These are herein
referred to as large-open HSRs, to distinguish them from the open HSRs of VP16 and
BRCA1. Quantification of chromatin unfolding capabilities (Figure 3.3D) demonstrates
that Myc is more potent at decondensing chromatin than BRCA1 or VP16 [140].
Detailed analysis showed that ~70% of LacI-Myc targeted HSRs became large open,
compared with ~15% of LacI-ΔMyc targeted HSRs (Figure 3.3E). The majority of LacIΔMyc HSRs (>50%) have failed to open and are classified as closed. LacI-BRCA1 (6cw) also have ~70% open HSRs, however they are small open and look significantly
different to LacI-Myc open HSRs (compare Figure 3.3B and C). The vast majority of
LacI-DBD HSRs are closed as expected. LacI-DBD is expressed at higher levels than
the other proteins, suggesting that the inability to open HSRs is not due to protein
crowding effects [140]. Myc is a relatively weak transcription factor, but it is now the
most powerful chromatin unfolding protein we have ever tested in this system.

Myc-Driven Chromatin Unfolding Requires MBII and Max Interactions
We next determined which functional domains in the Myc protein were required
for Myc-driven chromatin unfolding. The targeting of ΔMyc (missing MBII domain)
resulted in mostly closed HSRs (Figure 3.3E). A series of LacI-Myc mutants were
created and compared quantitatively to wildtype Myc for their ability to promote
chromatin decondensation. Loss of MBI, MBIIIa, MBIIIb and MBIV (but with the NLS
intact) did not affect the ability of Myc to unfold chromatin (Figure 3.3F). However, loss
of MBII renders Myc unable to induce chromatin unfolding, resulting in primarily closed
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Figure 3.3. Myc-Targeting Induces Large-Scale Chromatin Unfolding.
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Figure 3.3 (continued). (A) Schematic to describe the chromatin remodeling system
utilized in the CHO (A03_1) cell line used in (B-H). (B) LacI-DBD, LacI-BRCA1 (6c-w) or
LacI-VP16 were transiently expressed in CHO cells, followed by Immunofluorescence
(IF) with anti-LacI and FITC to detect open or closed HSRs. Nuclei were stained with
DAPI. (C) LacI-Myc was expressed and analyzed by IF to detect chromatin
decondensation. (D) Graphical representation of effects of the indicated LacI fusion
proteins on the ability to decondense chromatin. For each protein, at least 100
transfected cells were scored in triplicate, ±1SD. (E) Examples of LacI-MycΔMBII
targeted HSRs. (F) LacI-Myc deletion (Δ) mutants and a basic region missense mutant
(BM) were created and tested for their ability to decondense chromatin. At least 100
transfected cells were scored in triplicate, ±1SD. (G) Immunoblot of LacI-Myc mutants
from panel (F). (H) Co-localization of endogenous Max with LacI-Myc large open HSRs.

HSRs. Mutation of the basic region site where Myc binds to DNA was not required for
chromatin unfolding, but this is expected as we are targeting Myc to DNA through the
LacI binding (Figure 3.3F). Deletion of both the basic region and the HLH-LZ Max
binding domain (mutant ΔC) rendered Myc unable to decondense the HSRs. All
proteins expressed similarly (Figure 3.3G). Endogenous Max is strongly recruited to
Myc-unfolded HSRs (Figure 3.3H). These results suggest that Myc-Max interactions are
involved in the mechanism underlying chromatin decondensation by Myc. We conclude
from these results that targeting Myc to chromosomal regions in vivo causes a dramatic
chromatin-unfolding event that is strongly linked to the presence of the MBII domain.

Myc-Induced Chromatin Unfolding Does Not Effect MCM Chromatin Distribution
We next asked whether chromatin decondensation by Myc promoted the
assembly of CMG helicases by looking first at the MCM complex. Our group has
previously published that chromatin unfolding by Cdt1 facilitates MCM recruitment to
open HSRs through HBO1 recruitment [140]. This is a physiologically relevant result as
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Cdt1 is involved in the loading of MCM complexes onto chromatin. Using this result as a
positive control, we targeted Cdt1 to the HSRs and saw an enrichment of endogenous
chromatin-bound Mcm7 to Cdt1-open HSRs (Figure 3.4A, left). We then targeted LacIMyc, and in contrast to Cdt1, we did not see enrichment of endogenous chromatinbound Mcm7 to Myc-open HSRs (Figure 3.4A, right). However, Mcm7 is present in
open HSRs, but it is not enriched above the general chromatin stain seen throughout
the nucleus. We looked for chromatin enrichment of another MCM subunit, Mcm4, in
Myc open HSRs, and saw a lack of enrichment for endogenous Mcm4 (Figure 3.4B),
but the presence of light Mcm4 staining, as seen with Mcm7. At the boundaries of the
large-open HSRs MCM staining is brighter due to the higher density of chromatin. We
previously showed in Figure 3.1H that there was a lack of Mcm2 enrichment on
chromatin in the induced MK-MycER cell line at 15hrs (early-S phase), so we next
asked whether this could also be seen by immunofluorescence. In synchronized MKMycER cells induced at 0hr with 4-OHT and stained for Mcm2 at 15hrs we saw a lack of
co-localization of MycER (i.e. the overexpressed Myc) with the tightly-bound chromatin
complement of endogenous Mcm2 in 74% of the HSRs examined (Figure 3.4C,
quantified in Figure 3.8). Quantification of several hundred cells across multiple fields
was classified as high, moderate or low colocalization, and Mcm2 overlap with MycER
was moderate 26% of the time. We conclude that targeting Myc to chromosomal
regions to elicit chromatin unfolding does not result in the enrichment of the MCM
complex. This finding is also consistent with other studies showing that Myc does not
regulate MCM loading [14].
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Figure 3.4. Myc Induced Chromatin Unfolding Does Not Effect MCM Chromatin
Distribution. In all panels, transfected cells were pre-extracted with a Triton X-100
buffer to remove any proteins not tightly bound to chromatin. (A) Equal concentrations
of LacI-Cdt1 or LacI-Myc were expressed in CHO cells, followed by IF with antiLacI/FITC and anti-Mcm7/Texas Red to detect endogenous (endog) Mcm7. Nuclei were
stained with DAPI. White arrows indicate HSR region. Representative pictures of at
least 50 transfected cells. (B) LacI-Myc was expressed, followed by IF with antiLacI/FITC and anti-Mcm4/Texas Red to detect endogenous Mcm4. (C) Synchronized
MK-MycER cells were treated with 4-OHT at EGF readdition (0hr), pre-extracted and
fixed at 15hrs, followed by IF with anti-ER and anti-Mcm2 to detect endogenous Mcm2.
Representative images from three fields, with experiment conducted in duplicate.
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Chromatin Decondensation by Myc Stimulates CMG Helicase Assembly and
Activation
While we have demonstrated a lack of MCM complex enrichment at Myc open
chromosomal regions, MCM complexes are loaded onto chromatin in excess and only
certain MCM complexes are chosen to become CMG helicases. Myc functions
upstream of Cdc45 loading onto CMG helicases, although how and if Myc regulates
Cdc45 loading in any direct manner is known. We asked whether chromatin
decondensation by Myc promoted the recruitment of Cdc45 and GINS onto the MCM
complexes to assemble CMG helicases, and whether these helicase then became
active. The normal endogenous Cdc45 staining pattern is punctate and distributed
evenly throughout the nucleus (example in Figure 3.5A). When Myc was targeted to
HSRs and elicited a successful chromatin-unfolding event, chromatin-bound
endogenous Cdc45 was dramatically enriched (Figure 3.5B). The Cdc45 staining has
been depleted from the rest of the nucleus and the vast majority of the protein seems to
be localized to the 90 Mb region of the decondensed HSR. Cdc45 is extremely ratelimiting for DNA replication and CMG helicase assembly [17], and Myc targeting to the
HSR is sequestering the whole Cdc45 supply of the cell to one chromosomal region at
the expense of the rest of the replicating DNA in the nucleus. We asked whether the
presence of Myc alone at the HSRs caused co-localization of Cdc45 by analyzing the
rare closed HSRs targeted by Myc. Cdc45 was not enriched at Myc-targeted closed
HSRs (Figure 3.5C). Over 80% of HSRs targeted with Myc had Cdc45 enrichment
compared with only 20% for ΔMyc (Figure 3.5D). The vast majority of Myc-targeted,
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large-open HSRs were enriched for Cdc45 (>90%), with little to no enrichment of Cdc45
at small open or closed HSRs (Figure 3.5E). This demonstrates that robust chromatinunfolding event is required to recruit Cdc45 to chromatin. Chromatin-bound Cdc45 is
also dramatically co-localized with induced MycER in the synchronized MK cell line at
15hrs, as seen through significant spatial patterning overlap in nearly 100% of the
analyzed cells (Figure 3.5F and quantified in Figure 3.8), compared with little to no
overlap with Mcm2 in Figure 3.4C.
We asked whether chromatin unfolding elicited by other proteins also caused
enrichment of Cdc45 to the HSR region. Two other transcription factors known to elicit
chromatin unfolding, VP16 and BRCA1 (6c-w), were analyzed for Cdc45 enrichment.
Neither LacI-VP16 opened HSRs (Figure 3.5G) or LacI-BRCA1 open HSRs (Figure
3.5H) caused co-localization with Cdc45. This demonstrates that Myc-specific chromatin
decondensation is required for Cdc45 enrichment. Because Myc is a transcription
factor, we reasoned that Cdc45 recruitment to unfolded HSRs could be due indirectly to
LacI-Myc overexpression causing changes in the expression of an unknown protein that
itself promotes Cdc45 binding to HSRs unfolded by any protein capable of causing
chromatin decondensation. When a non-targeted HA-tagged Myc was co-expressed
with either LacI-VP16 (Figure 3.5I) or LacI-BRCA1 (Figure 3.5J), any transcriptional
effects Myc may be promoting did not cause Cdc45 to localize to the open HSRs of
these targeted proteins. This demonstrates the requirement for the physical presence of
Myc at chromosomal sites to promote Cdc45 enrichment, independent from its role as a
transcription factor. We conclude that Myc-mediated chromatin decondensation at Myc-
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targeted genomic sites is required for recruitment of the replication-limiting Cdc45
protein to chromatin.
We next asked whether Myc-targeted chromatin unfolding promoted the
assembly and activation of functional CMG helicases. We looked to see whether the
last member of the CMG helicase, the GINS protein complex, was enriched at Mycopen HSRs. We analyzed GINS by staining for one of its members Psf2, the staining
pattern for which was evenly distributed throughout the nucleus (Figure 3.5K). As we
found with Cdc45, chromatin-bound endogenous Psf2 was significantly enriched at
Myc-open HSRs (Figure 3.5L). Approximately 70% of HSRs targeted with Myc had Psf2
enrichment (Figure 3.5M), and as with Cdc45, the vast majority Myc targeted large open
HSRs had Psf2 enrichment (>80%), with only 30% enrichment at small open HSRs and
no enrichment at closed HSRs (Figure 3.5N). Chromatin-bound endogenous Psf2 was
also seen co-localized with induced MycER in the synchronized MK cell line at 15hrs in
83% of the analyzed cells (Figure 3.5O and quantified in Figure 3.8). We have
demonstrated that Myc-induced chromatin decondensation promotes the assembly of
CMG helicases, so we next asked whether these helicases become active through
looking at RPA co-localization, which binds to single-stranded (and thus unwound)
DNA, and BrdU incorporation (incorporated into newly synthesized DNA). The normal
staining pattern for RPA is evenly distributed throughout the nucleus (Figure 3.5P).
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Figure 3.5. Chromatin Decondensation by Myc Stimulates CMG Helicase
Assembly and Activation.
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Figure 3.5 (continued). Chromatin Decondensation by Myc Stimulates CMG
Helicase Assembly and Activation. CHO cells unless otherwise stated, equal
concentration of LacI-proteins expressed. In all panels, transfected cells were preextracted with a Triton X-100 buffer to remove any proteins not tightly bound to
chromatin. (A) Staining pattern of endogenous Cdc45.
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Figure 3.5 (continued). (B) IF of LacI-Myc open and closed HSRs (indicated by arrows)
with anti-LacI and anti-Cdc45 to show endogenous protein. (D) Quantification of
endogenous Cdc45 recruitment to HSRs targeted by LacI-Myc or LacI-ΔMyc. At least 50
HSRs analyzed in triplicate with ±1SD. (E) Cdc45 recruitment in LacI-Myc expressing
cells based on HSR size. (F) Synchronized MK-MycER cells induced with 4-OHT at 0hr
and analyzed by IF at 15hrs with anti-ER and anti-Cdc45 to detect endogenous Cdc45.
Representative images from three fields, with experiment conducted in duplicate. (G)
LacI-VP16 open HSRs showing lack of Cdc45 enrichment. (H) LacI-BRCA1 (6c-w)
HSRs showing lack of Cdc45 enrichment. (I) LacI-VP16 co-expressed with a nontargeted HA-Myc showing lack of Cdc45 enrichment at open HSRs. (J) LacI-BRCA1
(6c-w) co-expressed with a non-targeted HA-Myc showing lack of Cdc45 enrichment at
open HSRs. (K) Staining pattern of endogenous Psf2. (L) Psf2 enrichment to LacI-Myc
open HSRs. (M) Quantification of endogenous Psf2 recruitment HSRs targeted by LacIMyc. (N) Psf2 recruitment in LacI-Myc expressing cells based on HSR size. (O)
Synchronized MK-MycER cells induced with 4-OHT at 0hr and analyzed by IF at 15hrs
with anti-ER and anti-Psf2 to detect endogenous Psf2. Representative images from
three fields, with experiment conducted in duplicate. (P) Staining pattern of
endogenous RPA. (Q) RPA enrichment to LacI-Myc open HSRs. (R) Synchronized MKMycER cells induced with 4-OHT at 0hr and analyzed by IF at 15hrs with anti-ER and
anti-RPA32 to detect endogenous RPA. Representative images from three fields, with
experiment conducted in duplicate. (S) Synchronized MK-MycER cells induced with 4OHT at 0hr and pulsed with BrdU at 15hrs, IF with anti-ER and anti-BrdU.
Representative images from three fields, with experiment conducted in duplicate.

Chromatin-bound endogenous RPA was enriched at Myc-open HSRs (Figure
3.5Q) and was dramatically co-localized with MycER in 100% of induced MK-MycER
cells fixed and analyzed in early-S phase (Figure 3.5R and quantified in Figure 3.8). We
could not assess BrdU enrichment at Myc targeted HSRs, as no transfected cells were
BrdU positive. This could be due to two reasons. The first is that none of the cells we
observed were in S phase and so would not be BrdU positive. However, this is unlikely
since over 300 HSRs were examined, whereas for RPA staining (another indicator of S
phase) we observed amble enrichment. The second, more plausible explanation is that
the LacO-LacI binding affinity is too strong to allow the replication machinery to
progress through large chromatin regions and replicate DNA, however, the initial DNA
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unwinding can occur as indicated by RPA enrichment. We could however observe BrdU
co-localization with MycER in close to 100% of the induced MK-MycER cells assessed
in early-S phase (Figure 3.5S and quantified in Figure 3.8), as previously reported [14].
We conclude that chromatin decondensation by specifically by Myc promotes both CMG
helicase assembly and activation.

GCN5 and TIP60 Facilitate the Ability of Myc to Decondense Chromatin and
Recruit Cdc45
Myc has been shown to bind to genomic sites with histone H3 and H4
methylation and acetylation marks, associated with active and open chromatin, and
promote further acetylation of histone H4 tails [82]. Myc recruits the HATs GCN5 and
Tip60 to chromatin, and we asked if these potential mediators of Myc functions in vivo
played a functional role in the mechanism behind Myc-driven chromatin accessibility
and CMG formation [86, 88].
We reasoned that histone H4 modifications played a role in Myc-induced
chromatin unfolding. We co-expressed Myc with the Set8 histone methylase H4 binding
domain (Set8-HBD) (Figure 3.6A) which binds to histone H4 tails and blocks their posttranslational modifications, such as acetylation. As seen in Figure 3.6B, co-expression
of Set8-HBD significantly reduced the ability of Myc to elicit chromatin decondensation,
through an overall shift towards a less-unfolded chromatin state. This suggests that H4
acetylation modifications are likely involved in Myc-driven chromatin unfolding. Myc
interacts in vivo with the HATs GCN5 and Tip60 through the MBII domain. Myc open
HSRs showed enrichment of chromatin-bound endogenous GCN5 and Tip60, but not
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Figure 3.6. GCN5 and TIP60 Facilitate the Ability of Myc to Decondense Chromatin
and Recruit Cdc45.
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Figure 3.6 (continued). GCN5 and TIP60 Facilitate the Ability of Myc to
Decondense Chromatin and Recruit Cdc45. (CHO cells unless otherwise stated) (A)
IB of co-transfected LacI-Myc and Set 8-HBD in a 1:1 ratio. (B) Quantification of the
results from (A). (C) LacI-Myc open HSRs stained with anti-GCN5, anti-TIP60 or antiHBO1 to detect endogenous proteins. (D) IB of LacI-Myc or LacI-ΔMyc cells cotransfected with GCN5 or GCN5 mutant, ratio of 1µg LacI protein: 2µg GCN5.
Quantification of the effects of co-transfection of GCN5 or GCN5 mutant on LacI-Myc
(E) or LacI-ΔMyc (F) HSR size. At least 100 transfected cells were scored in triplicate,
±1SD. Representative of at least two experiments with similar results. (G) Quantification
of endogenous Cdc45 recruitment to HSRs targeted by LacI-Myc or LacI-ΔMyc in the
presence of GCN5 or mutant. (H) Synchronized MK-MycER cells analyzed by IF at
15hrs with anti-ER and anti-GCN5 to detect endogenous GCN5. (I) IB of LacI-Myc or
LacI-ΔMyc cells co-transfected with Tip60 or Tip60 mutant, ratio of 1µg LacI protein:
2µg Tip60. Quantification of the effect of co-transfection of Tip60 or Tip60 mutant on
LacI-Myc (J) or LacI-ΔMyc (K) HSR size.
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Figure 3.6 (continued). (L) Quantification of endogenous Cdc45 recruitment to HSRs
targeted by LacI-Myc or LacI-ΔMyc in the presence of Tip60 or Tip60 mutant. (M)
Synchronized MK-MycER cells analyzed by IF at 15hrs with anti-ER and anti-Tip60 to
detect endogenous Tip60.

HBO1, a HAT not associated with Myc-mediated acetylation (Figure 3.6C). This
demonstrates specificity for GCN5 and Tip60 recruitment by Myc.
We next asked whether GCN5 and Tip60 were required for Myc-driven chromatin
unfolding and Cdc45 recruitment. We co-expressed LacI-Myc or LacI-ΔMyc with GCN5
or a catalytically dead mutant GCN5 (Figure 3.6D). Expression of mutant GCN5 with
LacI-Myc produced a significant shift toward condensed HSRs, whereas expression of
wild-type GCN5 did not alter the chromatin opening dynamics (Figure 3.6E). The ability
of Myc to open chromatin is potent and it might not be possible to make it any better by
adding additional GCN5, however, a mutant GCN5 which can interact with the MBII
domain may be competing with endogenous GCN5 and preventing successful
chromatin decondensation by Myc. Expression of mutant GCN5 with LacI-ΔMyc did not
produce further closed HSRs, however, the expression of wild-type GCN5 facilitated the
opening of HSRs, thus overcoming the deficiency of MBII loss (Figure 3.6F). We next
asked how these results affected Cdc45 recruitment to HSRs, as a measure of CMG
helicase assembly. We found that expression of mutant GCN5 with LacI-Myc negatively
affected the number of Myc-targeted HSRs with Cdc45 recruitment, and wild-type
GCN5 facilitated Cdc45 recruitment to ΔMyc-targeted HSRs (Figure 3.6G). Chromatinbound endogenous GCN5 was also seen co-localized with induced MycER in the
synchronized MK cell line at 15hrs in 100% of the analyzed cells (Figure 3.6H and
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quantified in Figure 3.8). We next co-expressed LacI-Myc or LacI-ΔMyc with Tip60 or a
catalytically dead mutant Tip60 (Figure 3.6I). Expression of mutant Tip60 with LacI-Myc
caused a shift toward condensed HSRs, whereas expression of wild-type Tip60
produced no change (Figure 3.6J), as seen with GCN5. Expression of mutant Tip60
with LacI-ΔMyc had no effect, however, the expression of wild-type Tip60 produced an
overall shift towards the opening of LacI-ΔMyc targeted HSRs, and thus, like GCN5,
overcame the deficiency of MBII loss (Figure 3.6K). Expression of mutant Tip60 with
LacI-Myc negatively affected the number of Myc-targeted HSRs with Cdc45 recruitment,
and wild-type Tip60 facilitated Cdc45 recruitment to ΔMyc-targeted HSRs (Figure 3.6L),
as with GCN5. Chromatin-bound endogenous Tip60 was also seen co-localized
(although less dramatically than GCN5) with induced MycER in the synchronized MK
cell line at 15hrs in 96% of the analyzed cells (Figure 3.6M and quantified in Figure 3.8).
We conclude that the ability of Myc to elicit chromatin decondensation and Cdc45
recruitment is dependent on histone H4 modifications mediated through the recruitment
of the HATs GCN5 and Tip60 to chromatin through the MBII domain.

Myc and the MBII Domain are Required in Late G1-Phase for Cdc45 Recruitment
to Chromatin
Myc is an immediate-early gene product that is required for the transcriptional
induction of many early-G1 gene targets important for cell cycle progression into lateG1. Cdc45 loading onto MCM complexes during CMG helicase assembly occurs in lateG1 in mammalian cells released from quiescence [21]. While we have demonstrated
that overexpressed Myc causes Cdc45 recruitment to chromatin, leading to excessive

105

CMG helicase activation, it is unknown whether normal levels of endogenous Myc, and
specifically MBII function, are required in late-G1 at the time that Cdc45 normally loads
(~8hrs in MK cells). We wanted to retain the ability of Myc to induce early-G1 gene
transcription, and this is likely important for Cdc45 loading and many other late-G1
events, so we designed an experimental strategy (Figure 3.7A) in which synchronized
cells (MK-MycER and MK-ΔMycER) were released into G1 and at the same time were
transfected with siRNA targeting Myc or Luciferase. We predicted that there would be a
delayed loss of Myc protein level so that Myc would be present in early G1 for gene
activation, but would be absent by late-G1. Figure 3.7B shows that endogenous Myc
was indeed present in early-G1, but became progressively lost by late-G1. Although
ΔMycER protein expression was not affected by si-Myc treatment, MycER protein levels
were partially suppressed at later intervals (Figure 3.7B, 6hr and 8hr time points).
However, even under these conditions the MycER protein level is higher than the
endogenous Myc level by late-G1, and is high enough to rescue S phase entry, as seen
in Figure 3.7C. To test whether reduction of endogenous Myc affects transcription, we
looked at the protein level of monocarboxylate transporter 1 (MCT1), an established
Myc target gene [149]. This did not alter with endogenous Myc depletion (Figure 3.7B),
indicating that the early-G1 transcriptional effects elicited by Myc were still intact.
Delayed loss of endogenous Myc protein resulted in a block to S phase entry (Figure
3.7C), consistent with Myc function being required in late-G1 for entry into S phase [14].
However, activation of MycER (Figure 3.7C left) during si-treatment rescued the ability
of the cells to enter S phase, but in contrast, activation of ΔMycER did not (Figure 3.7C
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Figure 3.7. Myc and the MBII Domain are Required in Late G1-Phase for Cdc45
Recruitment to Chromatin.
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Figure 3.7 (continued). (A) Experimental design for panel (B) showing graphical
representation of expected rate of endogenous Myc loss. (B) MK-MycER and MKΔMycER were synchronized, and at time of EGF re-addition transfected with siRNA
against siLuciferase (control) or siMyc. Immunoblot probed with the indicated antibodies
at the indicated time points. (C) MK-MycER and MK-ΔMycER were synchronized, and
at time of EGF re-addition transfected with siRNA against siLuciferase or siMyc, ± 4OHT activation. Average number of BrdU positive cells at 15hr normalized to
percentage of siLuciferase control. Three fields analyzed ±1SD. (D) IB analysis total
protein expression and chromatin-bound complement of the indicated proteins at 15hrs
in synchronized MK-MycER and MK-ΔMycER treated with si-RNA at time of EGF readdition. (E) Our model of how Myc-induced chromatin unfolding is required for CMG
helicase assembly and activation.

right). We next asked whether loss of endogenous Myc by late-G1 affected the ability of
Cdc45 to load onto chromatin. In the absence of MycER activation, suppression of
endogenous Myc inhibited Cdc45 loading, although did not affect total Cdc45 protein
expression (Figure 3.7D, left). However, activation of MycER rescued Cdc45 loading
onto chromatin. This rescue was dependent on the presence of the MBII domain, as
activation of ΔMycER did not rescue Cdc45 loading onto chromatin (Figure 3.7D, right).
We conclude that there is a late-G1 dependence on endogenous normal Myc levels for
Cdc45 chromatin loading in order to assemble CMG helicases, which is dependent
upon the presence of the MBII domain. Figure 3.7E shows our model of how Myc
stimulates CMG helicase assembly and activation. At low Myc levels, chromatin is
condensed and MCM hexamers are inaccessible. At normal Myc levels, Myc is bound to
genomic promoter and intergenic regions, and creates chromatin accessibility through
GCN5 and Tip60 recruitment allowing access of the MCM complexes to form CMG
helicases. At overexpressed Myc levels Myc increasingly binds to intergenic regions,
where it creates more CMG helicases.
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Figure 3.8: Quantifications of the Protein Co-Localizations in Synchronized MycInduced MK-MycER cells. Cells were pre-extracted with Triton-X100, analyzed in Sphase at 15hr. Average of three fields ±1SD. IF examples of co-localization categories
(low, moderate or high co-localization) for Mcm2, Psf2 and Cdc45.
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Discussion

Myc is deregulated through amplification or constitutive activation in a large
variety of cancers and promotes oncogenesis through its role as a transcriptional
regulator of genes involved in cell cycle progression, metabolism, differentiation and
apoptosis. Myc deregulation can promote genomic instability, likely contributing to Mycdriven tumorigenesis. Part of the genomic instability incited by Myc is due to a nontranscriptional role in regulating the initiation of DNA replication. Myc is required for S
phase initiation, and overexpressed Myc causes excessive DNA replication due to
overactivation of CMG helicases [14, 78]. This overactivation produces DNA damage,
which could lead to the genomic instability incited by Myc. The mechanisms behind how
Myc stimulates excessive DNA replication through replicative helicase activation
remains poorly understood, and likely involves both transcriptional and nontranscriptional Myc-driven events. The oncogenic effects of Myc on the replication
machinery likely involve upregulation of genes necessary for helicase assembly and
activation, such as cyclin-cdk complexes, proteins involved in the loading of helicase
subunits, or the helicase subunits themselves [67, 80]. In this study we have provided
evidence for a novel mechanism for Myc mediated control over DNA replication
initiation. Myc creates higher order chromatin accessibility, which promotes CMG
helicase assembly and activation. The ability of Myc to regulate chromatin structure
could bridge the transcriptional and non-transcriptional roles for Myc in promoting
oncogenesis and normal cell cycle progression.
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Myc binds to a large number of genomic sites, both at normal and overexpressed
levels. While many of these sites are in the expected promoter regions of Myc-target
genes, a significant proportion are at large distances from transcriptional start sites in
intergenic regions, and this proportion increases when Myc is overexpressed [63, 64,
122]. Intergenic regions are where the start sites for DNA replication occur, and could
explain in part Myc’s presence there [13]. Myc targeting to genomic sites correlates with
pre-existing and subsequent chromatin modifications to these regions [139]. However,
the molecular and regulatory nature of these Myc-associated chromatin modifications is
not clear. To investigate how Myc functions to influence CMG helicase activation, and
whether chromatin modifications were involved in this mechanism, we utilized an
innovative engineered system that allows us to recapitulate many of the characteristics
of Myc, such as overexpression and intergenic DNA binding.
We discovered that for a relatively weak transcription factor, Myc is incredibly
robust at inducing large-scale chromatin decondensation at targeted genomic sites. This
chromatin modification required the highly conserved MBII domain of Myc, and involves
Max interactions. Two HATs that bind to Myc through the MBII domain and are known
physiological mediators of Myc-regulated processes, GCN5 and Tip60, are required for
Myc-mediated chromatin unfolding. To understand Myc’s effects on DNA replication we
looked at the recruitment of the CMG helicase members, and found that Myc-driven
chromatin decondensation stimulates the massive recruitment of GINS, and Cdc45,
which is extremely rate-limiting for mammalian helicase assembly and activation (see
Figure 3.9). Myc does not influence the distribution of MCM hexamers, but promotes the
formation of CMG helicases on the pre-loaded MCMs, which leads to helicase activation
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at Myc targeted genomic regions. This Myc-driven helicase assembly and activation is
dependent on the chromatin decondensation induced specifically by Myc being targeted
to the region. Our results correlate with other studies showing that Myc overexpression
leads to a higher number of active helicases per genomic region, increasing the
replication origin density and activation that creates DNA damage [78]. We have
demonstrated that normal levels of Myc also regulate Cdc45 recruitment during the cell
cycle, indicating that the elevated helicase activation following Myc deregulation is a
derivative of normal Myc function towards Cdc45 loading and this has become over
stimulated.
The wide distribution of Myc binding sites throughout the genome coupled with
Myc’s ability to cause potent chromatin unfolding over great distances provides an
intriguing model that explains the genomic influences of Myc (Figure 3.7E). Chromatin
unfolding by Myc stimulates CMG helicase activity in intergenic regions at a distance by
causing the chromatin accessibility that allows helicase assembly on the intergenic
MCM hexamers in the vicinity of Myc interactions. Myc interactions in the vicinity of
promoters will likely be associated with chromatin decondensation that stimulates
additional protein interactions that lead to transcriptional activation of Myc-target genes.
Overexpressed Myc would be able to expand its influences over genomic regions,
promoting a larger amount of chromatin decondensation that may alter transcriptional
activation or repression of additional genes or chromosomal processes, which may not
normally be under direct Myc control in an unperturbed state.
The ability of overexpressed Myc to induce chromatin accessibility and stimulate
excessive CMG helicase activation has important tumorigenic implications. An excess
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of MCM hexamers are loaded onto chromatin in mammalian cells than are needed for a
normal S phase initiation and completion. The excess MCM complexes act as backups/reserves that become new CMG helicase under conditions of replicative stress,
which stall replication forks [97]. This allows replication to be completed and maintains
genomic stability. The reserve MCM complexes are also necessary for a normal,
unperturbed S phase to complete without DNA damage occurring [43]. The reserve
MCMs become activated when replication forks stall due to normal S phase stresses
such as challenging topological issues or heterochromatin. Overexpression of Myc
causes the premature usage of these reserve complexes, converting them into active
CMG helicases to create smaller inter-origin distances [78]. However, this effectively
reduces the reserve complement, creating a deficiency in the ability of cells to recover
DNA replication following replicative stresses such as normal S phase conditions, or
from chemotherapy treatment, which indirectly stalls replication forks (Figure 3.9). A
Myc-driven lack of reserve MCM complexes could be an event that occurs early in Mycoverexpressed tumorigenesis, causing the accumulation of undetected DNA damage
that drives the oncogenic phenotype. Overexpressed Myc at any stage of tumorigenesis
would exacerbate genomic instability and promote additional chromosomal changes
arising from the unresolved DNA damage.
Myc-driven reduction in reserve MCM complexes could explain two paradoxical
findings regarding Myc overexpression in human cancers. Tumors with high Myc
expression are associated with poor survival rates and an aggressive phenotype [150],
and yet such cancers also respond better to chemotherapy regimens involving drugs
that cause replication forks to stall [142, 143, 151]. We have presented evidence that
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Figure 3.9: Myc Stimulation of CMG Helicase Assembly and Activation Causes a
Reduction in the Reserve MCM Complexes. Overexpressed Myc levels cause an
over-usage of MCM complexes, converting them into active CMG helicases. When
chemotherapy treatments cause replication forks to stall in S phase, there are no
reserve MCM complexes to function as new origins, and thus DNA replication fails to
recover, promoting DNA damage, which could lead to cell death or genomic instability.

shows acutely elevated Myc sensitizes tumor cells to replicative inhibitors such as
gemcitabine. As explained above, the loss of reserve MCMs due to overexpressed Myc
promotes DNA damage and genomic instability that are hallmarks of tumor progression,
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providing a reason for Myc-driven tumor aggressiveness and poor prognosis. Also the
same lack of reserve MCMs due to Myc overexpression means tumor cells are deficient
in recovering from the replicative stress of chemotherapy drugs, providing an
explanation for the better response to clinical intervention of Myc overexpressed tumors.
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CHAPTER FOUR:
CONCLUSIONS AND FUTURE DIRECTIONS

Conclusions

We hypothesized that the efficacy of the clinically relevant drugs gemcitabine and
5-FU against pancreatic cancer cells, and oxaliplatin and etoposide against colorectal
cells, could be increased through co-suppression of the reserve MCM complexes. Using
siRNA targeting of MCM subunits, depletion of the reserve MCM complexes caused
chemosensitization of multiple human tumor cell types to several chemotherapeutic
drugs used in the clinical management of human cancer. This was due in part to an
inability of such cells to recover DNA replication following drug treatment, which lead to
an increase in apoptosis. Depletion of reserve MCM complexes did not sensitize a nontransformed epithelial cell line to the same doses of gemcitabine that a PDAC cell line
was sensitized to. This argues for the development and use of anti-MCM drugs in
combination with chemotherapeutic compounds, which has the potential to increase the
therapeutic index of existing clinical compounds whilst minimizing side effects on normal
cells.
The oncogene c-MYC also leads to the mismanagement of CMG helicases in
part due to a non-transcriptional role in overactivating replication origins and causing
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DNA damage. We sought to elucidate the mechanism by which Myc causes
overactivation of CMG helicases. We have identified a previously unknown role for Myc
in normal cell cycle progression whereby Myc targeting to genomic sites induces
decondensation of higher-order chromatin structure that is required for the assembly
and activation of CMG helicases at reserve, accessible MCM hexamers, and
overexpression of Myc creates excessive helicase activation due to further Myc-driven
unfolding. Our results also provide new mechanistic insight into Myc oncogenic
transformation in which overstimulation of DNA replication could result in genomic
instability and provide an explanation for Myc driven oncogenic transformation.

Future Directions

Genomic Locations of CMG Helicase Proteins
A group published the genomic mapping sites of Cdc6 and Mcm7 [152]. This
group presented unpublished data at a Cold Spring Harbor meeting stating that they
followed up this study by classifying the Cdc6 and Mcm7 pre-RC sites into firing origins
and dormant origins. They found good correlation between firing pre-RCs and c-Myc
binding, and that firing origins have open chromatin structure (Sugimoto and Fujita
2015, unpublished data). This data supports my project and poses other questions,
such as what is the correlation of c-Myc binding sites with the genomic binding sites of
other CMG helicase proteins, especially Cdc45. If Cdc45 binding sites and c-Myc
binding sites overlap or are in a similar vicinity, this would support our work in chapter 3
showing co-localization of Cdc45 and Myc using immunofluorescence. Very little is
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known about how Cdc45 is loaded onto chromatin, and no experimental assay has
linked Myc and Cdc45 as being direct interactors. It would be interesting to elucidate the
recruiting and loading factors of Cdc45 onto DNA, and whether any of these factors
directly interact with Myc.

Direct Myc Interactions with the CMG Helicase
Myc has been found in complexes with members of the pre-RC proteins,
including Cdt1, Cdc6, ORC and MCM hexamers [14]. Co-immunoprecipitation using
anti-Myc also revealed interactions between Myc and Mcm3, 5 and 7, and Cdc6 [14]. It
is not known whether Cdc45 and the GINS proteins are also in these complexes, as
when this study was conducted the full complement of the replicative helicase was
unknown. An approach using tandem affinity purification with mass spectral
multidimensional protein identification technology (MudPIT) identified 221 c-Myc
associated proteins, of which only 17 were previously known interactors. Of particular
interest to this project is that Mcm7 was identified as a c-Myc interactor, and the
interaction of Myc with Mcm7 depended on the presence of the MBII domain [79]. The
C-terminal of Mcm7 was presumed to interact with Myc, as deletion of amino acids 1432 did not interfere with the associated with Myc [79]. Preliminary data we collected
also support these findings, as when we expressed ectopic HA-tagged Myc or ΔMyc
and Flag-tagged Mcm7 CT (C-Terminus) and performed an anti-HA coimmunoprecipitation, we could detect Mcm7-CT only with wild type Myc, and not ΔMyc
missing the MBII domain (Figure 4.1). We also saw that full length endogenous Mcm7
was co-precipitated with both Myc and ΔMyc, suggesting there may be other interaction
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sites or interaction partners between these proteins than just the MBII domain (Figure
4.1, bottom).
However, whether Myc makes a direct physical interaction with these proteins is
still uncertain, as there may be additional proteins that are forming complexes with Myc

Figure 4.1: Direct Interaction of the MBII Domain of Myc with the C-Terminus of
Mcm7. In HEK293T cells (human embryonic kidney cells), equal concentrations of HAtagged Myc or ΔMyc co-transfected with equal concentrations of Flag-tagged Mcm7-CT
(C-terminal 137 amino acids) or empty vector. Immunoprecipitation (IP) with anti-HA
antibody, immunoblot (IB) with anti-Flag to detect Mcm7-CT or anti-Mcm7 to detect full
length endogenous Mcm7.

and proteins such as Mcm7. To ascertain this in future studies, it would be of interest to
purify bacterially expressed Myc, the mutant ΔMyc, and the individual CMG helicase
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proteins, incubate them together, and determine whether they co-immunoprecipitate in
the absence of any other proteins that may be acting as an intermediate binding
partner. Our group previously used this approach to successfully demonstrate that the
N-terminal of Rb physically interacts with the C-terminal of Mcm7 [40]. This finding is
intriguing, as both Myc and Rb are binding to the same region of Mcm7, yet elicit
opposite effects on cell proliferation and DNA replication. Future studies could utilize the
cell-free Xenopus extracts to determine whether the Myc-Mcm7-CT interaction is
necessary for DNA replication to occur. Bacterially purified Mcm7-CT could be titrated
into the Myc-rich Xenopus extracts, and the DNA replication rate measured via 32-P
incorporation. If the Myc-Mcm7 interaction is necessary for replication to occur,
increasing the amounts of the competitive binder Mcm7-CT will cause replication rates
to decrease. It has been demonstrated that adding Myc into this system causes a doserelated increase in DNA replication [14]. Pre-incubation of Myc with Mcm7-CT may
prevent this increase. Collectively, these future studies would strengthen the position
that Myc is directly involved in the CMG helicase.

The MCMs and Cancer
The expression levels of the MCM complex have to be carefully regulated and
balanced to prevent genomic instability, a hallmark of cancer often caused by replicative
stress [153]. Recent high-throughput sequencing studies have found that in 10% of lung
squamous cell adenocarcinomas at least one MCM gene is amplified [154].
Overexpression of Mcm7 in mouse epidermal tissue predisposed the animals to
develop squamous cell carcinomas quicker and more frequently when exposed to
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carcinogens than their normal littermates [155]. Reduction of Mcm2 levels in mice
causes lymphomas and thymomas [156]. Point mutations in MCM genes are relatively
common in tumors, in a study of 178 tumor genomes 12% of lung squamous cell
carcinomas were found to contain at least one point mutation [154]. Single nucleotide
polymorphisms in MCM genes are commonly observed in normal human genomes, at
least some of which when recapitulated in budding yeast cause genomic instability,
suggesting these may generate genomic instability in susceptible individuals [157].
There is a list of MCM cancer alleles mutations in the cBioPortal
(http://www.cbioportal.org), many of which are found in the conserved ATPase motifs,
which may generate MCM complexes that are biochemically defective and lead to
reduced DNA replication [153].
From the indicated studies, it appears that both overexpression of the MCMs,
consistent with an oncogenic role, and underexpression of the MCMs, consistent with a
tumor suppressive role, are linked to cancer development [153]. As we showed in
Chapter 2, underexpression of MCMs likely leads to reduced DNA replication. Areas of
non-replicated DNA could lead to DNA damage and genomic instability which drive
tumorigenesis. Overexpression of MCMs could be causing inappropriate protein-protein
interactions that may be titrating out blockers of proliferation, such as overexpression of
Mcm7 binding to and blocking the ability of Rb to inhibit the CMG helicase [42]. Or
overexpression could affect the stoichiometric balance of the Mcm subunits, leading to
nonproductive complexes at the expense of active complexes [153]. In our work from
Chapter 3, we argued that overactivation of MCM complexes is causing an increase in
origin activity, which could leading to cancer formation due to decreased levels of

121

reserve MCM complexes. Overexpression of Mcm subunits at the genetic level could
also lead to this fate. In all these overexpression/over usage scenarios, the end result is
either direct or indirect cellular proliferation, which drives tumorigenesis [153].

Current CMG Helicase Drugs
To date only a few inhibitors have been developed that target the initiation of
DNA replication, and the development of drugs to target the MCM complex offers an
intriguing avenue for novel cancer treatments [153]. At least three different classes of
small molecule helicase inhibitors could be developed for use as chemotherapeutic
agents. The first class is enzymatic inhibitors that inhibit the MCM complexes ATPase
activity, either through blocking initiation of the unwinding of DNA, or the elongation of
the replication fork [153]. The drug heliquinomycin has been shown to inhibit the
unwinding properties of the Mcm467 sub-complex, although this may be through an
indirect mechanism through interactions with single-stranded that blocking the
unwinding of DNA [158]. The fluoroquinolone ciprofloxacin inhibits MCM helicase
activity in vitro, but whether this is direct, indirect or specific is not known [153]. The
second class of inhibitors would be compounds that disrupted physical or genetic
interactions between CMG helicase subunits and other proteins necessary for its
activation [153]. The third class of inhibitors would be molecules that modulate mcm
gene expression levels, to either block cell proliferation or return it to normal levels
[153]. Trichostatin A, a HDAC inhibitor, reduces MCM2 gene expression and causes
apoptosis in colon cancer cells [159]. Widdrol causes downregulation of MCM levels
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indirectly due to the compound causing double-stranded DNA breaks, which activates
an ATM/ATR checkpoint leading to MCM level reduction and growth inhibition [160].
The mentioned drugs are indirect inhibitors of the MCM complex. The development of
specific helicase inhibitors is still in its early days. Since we have shown in Chapter 2,
and others have shown, that reducing MCM protein levels sensitizes cells to other
replication inhibitors, such specific anti-MCM inhibitors could increase the efficacy of
existing chemotherapeutics against cancerous cells.

CMG Helicase Purification and Drug Development
Most of the mechanistic work to date on the MCM complex has been performed
in yeast or Drosophila MCM complexes, due to the ability to purify the CMG helicases
from these organisms in large quantities [153]. No high throughput biochemical screens
have been conducted on the mammalian MCM complex or CMG helicase due to the
fact that these have only recently been purified in small quantities, and large quantities
are needed to perform drug screens of inhibiting compounds [153]. There is a strong
evolutionary conservation between the MCM genes that makes it likely that information
from lower eukaryotes may also apply to human DNA replication [153].
In Chapter 3 we established that Myc is causing assembly and activation of CMG
helicases on open chromatin. Another way to test whether Myc is causing an increase
in the number of CMG helicases formed is to purify the CMG helicase in the presence
or absence of Myc. Each member of the human CMG helicase is created through a viral
vector at used to infect SF9-insect cells, which then create large quantities of each
individual protein. One or two of the proteins can be tagged for purification, for example,
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in our laboratory we tag Cdc45 to allow for purification of fully formed helicases. If a Myc
virus is also used to infect the insect cells along with the other 11 viruses, we could
establish if more CMG helicases are purified in the presence of Myc compared to the
absence of Myc by using the Cdc45 tag to compare the amount of Cdc45 not in
complexes to that in complexes with helicase subunits. A mutant ΔMyc virus could also
be made to establish whether this does not cause more helicases to form, as we
suspect from our findings in Chapter 3. Caveats to this experimental approach are that
other Myc cofactors are probably necessary for Myc to assemble helicases, and the
insect homologues of these proteins may not be similar enough to the human proteins
to help assemble human helicases.
To test whether Myc has a direct effect on CMG helicase activation, once the 11
member complex is purified, human Myc purified protein can be added to the helicase
activity assay to assess whether it helps the with the unwinding of the oligonucleotide
substrate. As only purified helicase proteins and Myc would be present in the reaction,
this would show whether Myc directly influences helicase activity, and the mutant ΔMyc
could be tested to see if it has no effect or is a negative regulator of helicase activity.
Although these might be interesting avenues to explore, our work in Chapter 3 eludes to
Myc having a more indirect role in helicase assembly and activation through chromatin
modifications, which these assays are not well equipped to test.
Our results from Chapter 2 indicate the need to develop specific antihelicase/MCM complex drugs for use in combination chemotherapy regimens. Due to
the hexameric organization of the MCM complex, it might prove difficult for cells to
develop drug resistance if multiple ATPase sites are targeted simultaneously, allowing
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for increased efficacy of an anti-MCM drug cocktail [153]. Our group recently published
a study showing that exon 7 in the N-terminus of Rb directly inhibits DNA replication
through inhibition of fully formed CMG helicases. By using smaller peptides of exon 7
we hope to find an inhibitor of the helicase that mimics Rb’s functions and can be used
in drug development to create an anti-helicase compound for use in cancer patients. We
are also purifying the human CMG helicase complex to run large-scale drug screening
to identify novel inhibitors of its function. As we saw in Chapter 2, inhibition of the
reserve MCM complexes could preferentially sensitize cancer cells to existing
chemotherapeutic agents whilst minimizing the side effects on normal cells, and would
thus be an ideal anti-cancer therapy but able to target multiple tumor types.
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